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1 Executive Summary
Introduction
In April 2010, the Initial Clinical Referral Standards (ICR) for Congenital Hypothyroidism (CHT) Expert
Working Group was convened as a sub-group of the Joint Standing Committee for Congenital
Hypothyroidism (CHT JSC) to review and revise the UK National Screening Programme Initial Clinical
Referral Standards after Newborn Screening for Congenital Hypothyroidism.
The review commenced with a systematic review of the published evidence undertaken by Dr R
Knowles and Ms F Olafsdottir.
Background to the Expert Working Group
The decision to form the ICR group was made at the last meeting of the CHT JSC in April 2010. The
group report to the Joint Standing Committee for endorsement and recommendation.
Recommendations are ratified by the Blood Spot Advisory Group (BSAG) and submitted to the Fetal
Maternal and Child Health sub Group (FMCH) of the National Screening Committee (NSC) for
approval of any changes to current policy.
At the meeting in April 2010, the JSC reviewed current policy and UK performance against national
standards and with European standards and guidelines. The group agreed to review the existing
(2005) UKNSPC standards and guidelines to support confirmatory diagnosis and initial management
for babies in whom CHT is suspected.
Between July 2010 and September 2011 the Expert Working Group, chaired by Dr T Cheetham met
on four occasions to review and revise the referral standards.
Scope of the review
• Screening result TSH cut-offs used to determine which infants are referred, not referred or
for whom a repeat test might be indicated (borderline)
• Diagnostic schedule for confirmatory diagnosis of CHT
• Initial treatment including timing, starting dose, formulation and frequency of follow up to
the point of diagnosis or definitive management.
• Communication flows
• Communication with parents
• To support the review process with evidence review and expert consensus where published
evidence is lacking
Exclusions
• Definition for Congenital Hypothyroidism
• Timing of bloodspot sampling
• Screening test methods (TSH)
• Policy for repeating screening in preterm infants
Expected outputs
Revised ‘Standards and guidelines for Initial Clinical Referral’
Evidence review (including tables where appropriate)
Possible recommendation for further research
Membership and meeting dates
Membership and meetings of the Expert Working Group (EWG) are detailed in Appendix 2. The EWG
met on four occasions and five subgroups were convened to review topic-specific Standards:
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The CHT Test Performance Group
The groups remit included review of:
 Screening result TSH cut-offs used to determine which infants are referred, not referred or
for whom a repeat test might be indicated (borderline).
 Referral of babies with positive screening results
 Communication flows
Changes summarised
The group recommended that:
1. Standards and guidelines which were generic to all screening standards should be omitted
from the revised standards, including the policy for screening preterm babies, guidelines on
screening and blood transfusion, responsibility for taking the sample, and information and
consent.
2. An additional section and algorithm that describes a standard pathway for blood spot testing
should be developed (this approach is consistent with other conditions).
3. There should be no change in the TSH cut off levels used to define CHT suspected, borderline
and not suspected.
4. Referral of all those with screening results indicating CHT is suspected should be to a
paediatric endocrine team (regional specialist team) or to a clearly identified lead
paediatrician with a special interest in CHT or experience of managing these patients.
5. Notification of presumptive positive children and results should be to the regional specialist
team
6. A standardised diagnostic and initial treatment protocol should be used for those referred
and treated for CHT respectively.
7. Communication of presumed positive screening results to parents should ideally be face-to-
face be undertaken by an informed health care professional with good knowledge and
experience of managing CHT.
The Referral Pathway Subgroup
The remit of the group included review of the referral pathway after a presumed positive screening
result. In July 2011, a questionnaire was sent to all 16 screening laboratories in the UK to get a better
understanding of the different models of care and to establish what works well.
Changes summarised
The group recommended that:
1. Babies with positive screening results for CHT should be referred by the laboratory the same
or next working day.
2. Referral should be to a paediatric endocrine team (regional specialist team) or to a clearly
identified lead paediatrician with a special interest in CHT or experience of managing these
patients (who has a designated trained deputy).
3. Clinicians should work to a common protocol and back up should be provided by the
regional specialist team.
4. Wherever possible parents should be offered an appointment with the paediatrician on the
same day or the next day after being informed of their baby’s positive screening result.
The Diagnostic Subgroup
The remit of the diagnostic subgroup included review of the investigations and imaging that might
be appropriate for confirming the diagnosis of CHT after a positive screen result. A number of
research articles on biochemical investigations were reviewed long with expert views on imaging. Dr
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Tony Sirimanna, was invited to the ICR meeting in July 2011 to consider the need for hearing tests in
addition to those offered in the newborn hearing screening programme
Changes summarised
Based on the available evidence, the group made specific recommendations about:
1. Confirmatory diagnostic tests to be undertaken in the baby
2. Investigations to be undertaken in the mother
3. Appropriate thyroid imaging
4. Confirmation of the diagnosis and exclusion of transient CHT at 2-3 years of age.
A diagnostic protocol has been developed to summarise the confirmation of diagnosis pathway.
The Treatment Group
The remit of the group included the standards relating to treatment initiation, including formulation,
timing and dose.
Changes summarised
The group recommended that:
1. There should be an additional standard for age at start of treatment when a ‘CHT is
suspected ‘result is preceded by borderline result. (Based on data from 2010/11, an
acceptable standard of 24 days and achievable standard of 21 days were proposed).
2. The starting dose of levothyroxine should be raised, licensed solutions should be
recommended and there should be increased monitoring in the first year of treatment.
Parent Communication Information Group
This group included two parents of children with CHT. The scope of the group was to review the
following leaflets and documents:
• CHT and Your Child leaflet
• CHT is Suspected leaflet
• Pre-Screening leaflet
• Communicating a request for a borderline repeat
• Communicating a screen positive result
Changes summarised
Suggested changes were presented to the ICR CHT on 16th September 2011. At a final meeting with
additional input from Ms S Langham and Dr R Knowles, amendments to ‘CHT and Your Child Leaflet’
and the ‘CHT is Suspected’ leaflet including images, text and web links were reviewed and agreed.
Combining both leaflets was considered, however it was decided that separate leaflets were more
appropriate.
Public Consultation
A public consultation on the proposed new standards was carried out in 2012. Any changes made to
the standards on the basis of the responses received are noted in this final version of the report.
Summary and Recommendations
This final report presents the revised standards, screening protocol and diagnostic protocol
developed by the Expert Working Group (Section 2) and finalised after public consultation, as well as
the evidence basis for the revised standards and guidelines (Sections 3 -12).
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2 Revised CHT ICR Standards, Screening and Diagnostic Protocols
Stage of process No. Standards
The screening
protocol
1 The initial screening sample
Thyroid stimulating hormone (TSH) analysis is performed on a single spot
from the initial dried blood sample.
Samples with TSH ≥ a preliminary threshold (analytical cut off*) of 8mU/L 
whole blood (WB) are re-tested in duplicate from the same card but on a
different spot(s).
Action is taken on the triplicate mean result.
Second sample – TSH is analysed in duplicate and action taken on
duplicate result.
(See Screening Protocol flow diagram)
Timeliness of analysis – analysis is timed to permit referral of screen
positive results within 2-4 working days of sample receipt.
*The analytical cut off is set at 20% below the screen action cut off of 10mU/L
WB to allow for the natural variation in the TSH assay (i.e. the coefficient of
variation, CV=10%) and to minimise the effect of volumetric variability that
occurs in dried blood spots.
Re-testing also acts as confirmation of correct sample identification.
Categorisation of
initial screen
result
2 Babies in whom the TSH concentration is <10mU/L WB in the initial
screening sample should be considered to have a negative screening
result for congenital hypothyroidism (CHT).
Report CHT not suspected.
3 Babies in whom the TSH concentration is ≥ 20mU/L WB on the initial
screening sample should be considered to have a positive screening result
for CHT.
Report and refer as CHT suspected.
4 Babies in whom the TSH concentration is ≥ 10 and <20mU/L WB on the
initial screening sample should be considered to have a borderline result
for CHT.
Borderline
screen result
5 On detecting a borderline result a second blood spot sample is to be taken
7-10 days after the initial sample.
6 If the TSH concentration is <10mU/L WB in this second sample, the baby
should be considered to have a negative screening result for CHT.
Report CHT not suspected.
7 If the TSH concentration is ≥ 10mU/L WB in this second sample:
Report and refer as CHT suspected.
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Stage of process No Standards
Referral of
babies with
positive
screening results
8 The laboratory shall refer babies with positive screening results for CHT the
same or next working day.
Referral is to a paediatric endocrine team (regional specialist team) or to a
clearly identified lead paediatrician with a special interest in CHT or
experience of managing these patients.
Appropriate failsafe mechanisms must be in place to ensure CHT suspected babies
have entered into the diagnostic pathway.
Clinicians should work to a common protocol and have access to the full
range of diagnostic investigations recommended.
Where referral is out-with a regional endocrine centre, the regional
specialist team should be able to provide support and facilitate access to
diagnostic investigations where required.
9 The first clinical appointment with the paediatrician must take place on the
same day or the next day after parents are informed of their baby’s positive
screening result.
Communication
flows
10 Laboratories shall notify a positive screening test (blood spot results
expressed as a whole number), verbally and in writing by secure fax or
email, to the lead paediatrician or deputy and the health professional
responsible for communicating results.
This notification should include a link to the standardised diagnostic and
initial treatment protocol.
This initiates the clinical referral of screen positive cases.
11 The result should be communicated by an informed health professional.
The health professional making initial contact should provide the following
information to the family:
a) UKNSPC standardised parent information ‘When CHT is suspected’
(via hard copy or web link).
b) Details of the time and date of the appointment with the
paediatrician and appropriate contact telephone numbers.
12 The outcome of the first appointment should be reported to the newborn
screening laboratory.
The regional endocrine centre should also be informed about diagnostic
outcome to facilitate regional and national audit.
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Stage of process No Standards
Clinical
evaluation and
confirmatory
diagnostic tests
13 The clinician responsible for assessing the baby with a positive screening
result shall take a clinical history and perform a clinical exam
(See Note 1)
Note 1: Babies with CHT are more likely to have associated anomalies, particularly congenital
heart defects and mild hearing loss and require careful neonatal examination. A complete
history, including maternal thyroid status (previous history of thyroid dysfunction, maternal
anti-thyroid medications), maternal diet (e.g. vegan or other low iodine diet) and family
history should be obtained.
14 Diagnostic tests considered essential in the baby are:
a) freeT4 (plasma or serum)
b) TSH (plasma or serum)
(See Note 2)
Note 2: Diagnosis using freeT4 and TSH should be performed on a plasma or serum sample
using the appropriate age-related reference range as defined by the laboratory in relation to
the equipment used.
Desirable
additional
diagnostic tests
15 Appropriate imaging techniques (radio-isotope and/or ultrasound scans), may
help to establish whether the thyroid gland is
a) normally situated and normal in size and shape
b) normally situated but abnormal in size and shape
c) ectopic
d) absent
(See Note 3)
Note 3: A radioisotope scan and an ultrasound examination may establish the cause of the
child’s CHT and indicate whether the condition is likely to be permanent. Initiation of
treatment should not be delayed whilst waiting for an isotope scan, which can be performed
up to 5 days after starting therapy. An ultrasound scan can be performed at any stage and
investigation need not be confined to the neonatal period. These investigations may increase
awareness of potentially related problems such as deafness and can provide information
about recurrence risk. Recurrence is unusual in the case of thyroid dysgenesis but there is
likely to be autosomal recessive inheritance with a 1:4 recurrence risk for families of babies
with thyroid dyshormonogenesis. Both isotope scanning and thyroid ultrasound in neonates
require specialist skills and can generate misleading results.
16 In addition, the following test may be helpful:
a) Thyroglobulin
(See Note 4)
Note 4: Plasma thyroglobulin needs to be measured on a sample taken prior to the start of
treatment; this must not delay initiation of treatment. If plasma thyroglobulin is detectable
then there must be some thyroid tissue present. Concentrations will be undetectable in
thyroid agenesis.
Advisable tests
in the mother
17 Diagnostic tests considered advisable in the mother to exclude interference in
the infant’s TSH measurement and to exclude thyroid dysfunction in the
mother include:
a) freeT4 (plasma or serum)
b) TSH (plasma or serum)
These investigations should be extended to include an assessment of TSH
antibody receptor status in mothers with a current or previous history of
autoimmune thyroid disease.
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Stage of process No Standards
Treatment 18 A baby in whom a diagnosis of CHT has been made, should commence
treatment with oral levothyroxine by:
a) CHT positive on initial screening sample
Acceptable standard: 17 days of age (≥99% of infants) 
Achievable standard: 14 days of age (≥99% of infants) 
b) CHT positive on a repeat blood spot sample
Acceptable standard:24 days of age (≥99% of infants) 
Achievable standard: 21 days of age (≥99% of infants) 
19 The starting dose of oral levothyroxine should be 10-15mcg/kg/day, with a
maximum dose of 50mcg/day. The objective of treatment is to normalise TSH
within the first month. The dose of levothyroxine may need to be reduced if
TSH is suppressed or if the baby is showing signs of overtreatment.
Babies with significant endogenous thyroid hormone production may need
smaller initial doses.
(See Note 5)
Note 5: Treatment with levothyroxine should lead to normalisation of free T4 and a 50%
reduction in TSH within days. However, TSH normalisation can take weeks and timing does
not correlate well with the administered levothyroxine dosage or the severity of the
underlying diagnosis. The aim of treatment is therefore to increase free T4 close to the upper
reference range within the first 2 weeks of treatment and to normalise the TSH within the
first month. Free T4 concentrations may exceed the normal reference range at the time of
TSH normalisation but significant elevation should be avoided. Regular dose adjustments
may be required.
20 Only licensed solutions and tablets of levothyroxine should be used.
Suspensions may be unreliable. Parents should be shown how to administer
preparations and accompanying written information should be provided.
21 Once levothyroxine treatment has been started, TSH and thyroid hormone
concentration should be checked at an appointment with a paediatrician at
approximately 2 weeks, 4 weeks, 8 weeks, 3 months, 6 months, 9 months and
12 months after treatment is started, and thereafter as indicated. More
intensive biochemical monitoring may be required.
(See Note 5)
22 Assessment of Permanence of Hypothyroidism. In cases where the cause or
persistence/permanence of hypothyroidism has not been confirmed (see
Diagnostic Protocol flow diagram), confirmatory testing should be undertaken
at 2-3 years of age with thyroid function tests checked 4-6 weeks later..
The outcome should be fed back to the regional endocrine centre to facilitate
regional and national audit.
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Screening Protocol Flow Diagram
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Diagnostic Protocol Flow Diagram
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3 Introduction to Newborn Screening for Congenital
Hypothyroidism
3.1 Congenital hypothyroidism
Congenital hypothyroidism (CHT) is a disorder of the thyroid gland, which is normally situated at the
front of the neck. The thyroid gland produces a hormone called thyroxine, which is needed for
normal growth and development. If the thyroid gland does not produce enough thyroxine, it causes
hypothyroidism and, when this disorder is present from birth, it is called congenital hypothyroidism
(CHT). In babies with CHT, the thyroid gland either fails to develop normally (dysgenesis) or does not
work properly to produce adequate hormone (dyshormonogenesis). The production of thyroxine by
the thyroid gland is regulated by thyroid-stimulating hormone which is released by the pituitary
gland in the brain.
Most babies with CHT in the UK are detected by the newborn screening bloodspot programme
before they have any symptoms. However, if signs and symptoms are present, these may include
feeding difficulties, sleepiness, constipation and jaundice. If CHT is not diagnosed and treated soon
after birth, it can cause problems with mental development, clumsiness and abnormal growth. CHT
is treated by lifelong replacement of thyroid hormone, usually as levothyroxine sodium given daily
by mouth.
In the UK, around one in every 3,500 newborn babies has CHT and the disorder is more common in
girls than boys.
3.2 Newborn screening for CHT
Newborn screening for CHT was introduced in the UK in the 1970s.The aim of screening in the UK is
to prevent adverse neurodevelopmental outcomes by identifying infants with primary CHT due to an
abnormal or absent thyroid gland and to initiate treatment by 14-17 days of age.1 2 UK babies are
screened for CHT by looking for raised levels of thyroid-stimulating hormone (TSH) in the newborn
bloodspot (in whole blood) at 5-8 days of age. The sensitivity of this screening test is generally
considered to be very good but, as the TSH assay has become more refined, there has been a
tendency to set lower thresholds at which diagnostic investigation is indicated.3 A raised TSH
concentration at birth may also be a transient phenomenon, particularly in preterm infants and in
babies who are unwell or exposed to certain drugs. In the UK, a repeat screening test is conducted in
babies born at less than 32 weeks gestation as these preterm infants are more likely to have an
inappropriately low TSH level.4 The diagnosis of CHT is confirmed by measuring serum TSH and
serum thyroxine (T4) levels in a venous blood sample. Investigations such as ultrasound and radio-
isotope scanning of the neck can be used to determine the specific underlying thyroid abnormality
(dysgenesis or dyshormonogenesis).
Internationally, different methods are used for newborn screening. In most European countries a
whole blood TSH assay is initially performed on the newborn bloodspot although the threshold
chosen for a positive result may vary.5 In contrast, North American screening programmes often
measure whole blood T4 levels in the bloodspot initially and then undertake whole blood TSH
measurements as required for confirmation.
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4 Initial Clinical Referral Standards Review Expert Working Group
An Expert Working Group (EWG) was established in July 2010 by the UK Newborn Screening
Programme Centre (UKNSPC) with the aim of reviewing the existing Initial Clinical Referral Standards
(ICR) for Congenital Hypothyroidism (2005). Terms of reference are provided in Appendix 1. These
standards provide the standards and guidelines for best practice in investigating and confirming the
diagnosis of CHT after newborn screening, as well as communicating with parents and initiating
management for babies in whom CHT is suspected.
The EWG was chaired by Dr Tim Cheetham, Paediatric Endocrinologist, and members are listed in
Appendix 2.The Expert Working Group met on four occasions. Five subgroups (Appendix 2) focusing
on specific standards were constituted from the Working Group members; each subgroup met on
average on two occasions and then presented recommendations to the Expert Working Group for
approval. In 14th December 2011, the Expert Working Group recommendations for revised ICR
standards were presented to the UKNSPC Joint Standing Committee for CHT.
An evidence review (Olafsdottir and Knowles, 2010) to inform the development of revised ICR
standards was commissioned by the UKNSPC and presented to the first meeting of the EWG.
The review excluded screening of preterm infants as review of this policy was the responsibility of
another working group.
5 Systematic Literature Review and Evidence Synthesis
The methodology for the systematic literature review and evidence synthesis is described here and
the findings are presented in Sections 7-11. The report is divided into sections corresponding to the
standards reviewed by each topic subgroup.
5.1 Aim of the systematic review
Test performance
With regard to the screening test performance,
 To clarify the appropriate screening test TSH value at which infants should be referred for
diagnostic investigation (positive result), a repeat screening test might be indicated (borderline
result) or a negative screening result should be reported.
Screening result
After a positive test result, to define the
 Referral pathway and timeliness of referral by laboratory to designated clinician
 Referral pathway and timeliness of first visit to a designated clinician when a ‘CHT is suspected’
result is given after the first test result.
After a borderline test result, to define the
 Referral pathway and timeliness of repeat test for an initial borderline result
 Referral pathway and timeliness of referral to a designated clinician when a ‘CHT is suspected
‘result is preceded by borderline result.
After a positive or borderline test result, to define the
 Diagnostic schedule for confirmatory diagnosis of CHT
 Initial treatment including starting dose, formulation
 Frequency of follow up and repeat blood tests, including review to exclude transient CHT
 Standards for communication about the condition, investigations and treatment to parents.
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A secondary aim was to consider the evidence for the economic effectiveness of the
recommended pathways for screening, diagnostic referral and investigation, and on-going
management.
5.2 Methodology for the systematic review
Literature Search Strategy
Embase, Medline, PsychInfo and Cochrane Trials Register were searched for the period up to June
2010, without imposing any language restrictions, to identify all abstracts of papers relevant to
newborn screening for congenital hypothyroidism. Seven search concepts were developed through
the combination of various search terms, including ‘Congenital Hypothyroidism’, ‘Newborn’,
‘Screening’, ‘Diagnosis’, ‘Outcome’, ‘Treatment’ and ‘Economics’. Finally, to facilitate the exclusion of
papers that were not relevant to UK screening practice, a ‘Countries’ concept was developed to
include only European countries, Canada, the USA, Australia, New Zealand and Japan. The search
terms included within each concept are detailed in Box 1.
Box 1: Search terms included within each search concept
Search Concept Search terms within each concept
Congenital Hypothyroidism (CHT) congenital adj2 hypothyroid*
primary adj2 hypothyroid*
cretin*
myxodem*
myxoedem*
Newborn Newborn
Infant
neonat*
Screening screen*
Diagnosis diagnos*
manage*
Outcome biomark*
development*
IQ
Growth
behaviour*
social*
psycho*
Treatment treatm*
therap*
drug*
manage*
Economics econom*
cost*
financ*
Initially, a general search was carried out combining the CHT, Newborn, Screening and Countries
concepts. Following this, searches were carried out that excluded the Screening concept, in order to
identify any additional relevant papers that did not contain the search term screen*. Reviews were
excluded during abstract selection (see Box 2 for exclusion criteria); however reference lists of all
review papers retrieved by the searches were searched in order to identify additional papers.
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Abstract Selection
All retrieved abstracts were reviewed against the inclusion and exclusion criteria in Box 2.
Box 2: Inclusion and Exclusion Criteria for Abstract and Study Selection
Inclusion criteria Exclusion criteria
Studies of newborn screening for CHT
involving  20 participants
Studies of CHT focusing on incidence rate, aetiology,
iodine deficiency and/or associated anomalies
Papers published before July 2010 Screening practices not relevant to the UK (e.g.
screening using T4 or a combined T4/TSH test on
the newborn bloodspot, using cord blood, or
selecting infants)*
Studies from countries with newborn
screening and management practices
relevant to the UK
Papers reporting experience with ‘pilot’ screening
programmes (established for <3 years)
Screening for CHT undertaken within the
newborn period (first 6 months of life)
Studies involving less than 20 participants§
Screening test using TSH assay on the
newborn bloodspot (relevant to UK testing
at 5-8 days of age)
Review papers
*The exclusion criterion involving the screening assay (i.e. whether TSH alone or TSH and T4 were measured)
was not applied to studies that only reported longer-term outcomes for children living with CHT. Such studies
were included if (1) the method of detection was through newborn bloodspot screening and (2) treatment was
offered early in life.
§One study retrieved through Embase addressed parent responses to false positive screening results6 – this
paper was exceptionally included as (1) the qualitative methodology did not necessitate a larger sample size
for validity and (2) no other studies focused on this research question for parents of children with CHT were
identified.
Papers which concerned reviews of previously published studies, were searched for relevant
references and useful background information but were not included in the systematic review. All
papers (n=498) retrieved from the first search, undertaken through Embase, were reviewed against
the inclusion and exclusion criteria by two reviewers (FO and RK), and inter-rater agreement was
evaluated. As the agreement was high for this initial search (82%), one reviewer (FO) searched
through the remaining abstracts.
Table 1: Agreement between reviewers on abstract selection (including kappa statistic)
Reviewer 2
Reviewer 1 Exclude Include Total
Exclude 201 59 260
Include 31 207 238
Total 232 266 498
Statistical analysis
Actual agreement 82%
Expected agreement 50%
Kappa statistic 0.64
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Data Extraction
A hard copy of every paper that met the abstract selection criteria was retrieved, and data extracted
from each paper by one reviewer (FO). The data extraction sheet was developed through an iterative
process involving pre-specifying data required to address the research questions, testing on a small
sample of papers and further refinement of the data extraction sheet based on the results. The final
data extraction sheet recorded details of screening, re-screening and diagnostic methods used by
each study, such as type of test, timing, cut-off values, sensitivity, specificity, positive predictive
value and false positive rate. Moreover, details relating to management were also recorded, such as
timing, dosage, formulation, type and frequency of clinical review. Finally, details of outcomes were
noted, including the tests of outcomes used, length of follow-up, key results and conclusions.
Box 3: The GRADE approach to quality rating
*Systematic reviews were also rated as high if these conformed to Cochrane-type methodology.
Levels of quality for evidence using the GRADE approach
Underlying methodology Quality rating
Randomized trials; or double-upgraded observational studies.* High
Downgraded randomized trials; or upgraded observational studies. Moderate
Double-downgraded randomized trials; or observational studies. Low
Triple-downgraded randomized trials; or downgraded observational studies; or
case series/case reports.
Very low
Factors that may decrease the quality level of a body of evidence
1. Limitations in the design and implementation of available studies suggesting high likelihood of
bias.
2. Indirectness of evidence (indirect population, intervention, control, outcomes).
3. Unexplained heterogeneity or inconsistency of results (including problems with subgroup
analyses).
4. Imprecision of results (wide confidence intervals).
5. High probability of publication bias.
Factors that may increase the quality level of a body of evidence
1. Large magnitude of effect.
2. All plausible confounding would reduce a demonstrated effect or suggest a spurious effect when
results show no effect.
3. Dose-response gradient.
Quality assessment
Each paper included in the review was assigned a quality rating by the reviewer (FO) at the time of
data extraction. Ratings were based on the GRADE approach developed by the Cochrane
Collaboration (see Box 3 above).
Initial ratings were based on the study design alone but these were then increased or decreased if a
study had additional features influencing quality. Papers were given one of the following ratings for
quality: Low, (L), Medium (M), and High (H). Due to the large number of papers receiving M quality
rating, these papers were quality rated a second time, and assigned either a – or + rating.
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5.3 Papers retrieved for review
A total of 116 papers were included in the review (Figure 1). Initial searches through Embase
retrieved the majority of papers and, of 498 abstracts retrieved, 81 papers were included. Further
searches retrieved a total of six papers from the Medline database. No papers were found through
PsychInfo. One systematic review of levothyroxine dosage was identified through the Cochrane
Trials Register.
Sixteen review papers were retrieved by the general search through the Embase database. Three
additional review papers were identified through searching through reference lists of these review
papers. Reference lists of these review papers were searched in order to identify any additional
papers that had been missed by the electronic searches. This search yielded 25 more papers to be
included in the literature review.
Evidence from the retrieved papers, relevant to each of the specific research objectives, are
reviewed and discussed under each section of the report below.
Figure 1: Flowchart of search strategy and abstract selection process
Main search
EMBASE: Abstracts
retrieved: 498
Did not meet selection
criteria: 339
Not UK relevant: 78
Abstracts Included: 81
116
MEDLINE: Additional
abstracts retrieved: 38
Abstracts included: 9
Did not meet inclusion
criteria: 28
Not UK-relevant: 1
Reference list abstracts
included: 25
Review papers: 19
(includes Cochrane
review)
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6 Results of the EWG and Literature Review
Published evidence from the literature review, additional unpublished evidence and expert views
were considered by topic-specific subgroups and an interpretation of the evidence presented to the
EWG. The EWG considered this evidence then made recommendations for revisions to the ICR
Standards.
In this section of the report, the evidence considered by each subgroup, and the final interpretation
of the evidence and recommendations of the EWG are presented by topic.
EWG Topic Subgroups
Each subgroup was allocated a range of topic-related standards to consider. The evidence report
was discussed by EWG subgroup members who then also sought additional evidence from published
and unpublished sources, as well as from invited experts, before revising the standards. Each set of
revised standards agreed by a subgroup was then brought to the full EWG as a set of recommended
revisions for approval. In a final meeting, the full EWG agreed the final revisions to be
recommended.
The evidence review and interpretation of this by the EWG is presented below, subdivided into five
sections corresponding to the topic subgroups of the EWG.
7 Performance of the TSH assay as a screening test
7.1 Original (2005) ICR standards relevant to screening test performance
The test performance subgroup considered the need for revisions to standards 1-10 from the 2005
document (Box 4).
EWG members drew on four sources of evidence:
 Evidence from the literature review of test performance by Ms F Olafsdottir & Dr R Knowles
 Minutes of the Initial Clinical Referral Standards Working Group of 2004 at which evidence
was discussed and current standards were established.
 Evidence from the Great Ormond St study of borderline screen test results from Dr C Peters
& Ms S Langham
 Evidence relating to the costs of ‘missed’ cases.
Final Report (January 2013) 20 | Page
Box 4: Standards 1 to 10 (2005)
1. Babies in whom the TSH concentration is greater than 20mU/L whole blood on the initial
screening sample should be considered to have a positive screening test result for CHT.
2. Babies in whom the TSH concentration lies between 10 and 20mU/L whole blood on the
initial screening sample should be considered to have a borderline result for CHT.
3. Babies in whom the thyroid stimulating hormone (TSH) concentration is less than 10mU/L
whole blood in the initial screening sample should be considered to have a negative
screening result for congenital hypothyroidism (CHT). Collection and assay of the blood spot
sample should not be delayed in premature infants for whom it should be repeated when
the baby attains the equivalent of 36 weeks gestation. Similarly it should not be delayed in
babies who have received a blood transfusion for whom the sample should be repeated 72
hours later.
4. On detecting a borderline screening result, a repeat assay should be performed on the
original blood spot card before a second blood spot sample is requested.
5. If the TSH concentration is less than 10mU/L whole blood in this second assay, the baby
should be considered to have a negative screening result for CHT.
6. If the TSH concentration is greater than or equal to 10mU/L whole blood in this second
assay, a second blood spot sample should be requested.
7. This second blood spot sample should be, taken by a midwife or if the baby is still in hospital,
by the clinician responsible for their clinical care.
8. Parents of babies with borderline results, irrespective of whether the baby is at home or in
hospital, should be informed of the reason for a second blood spot sample and given
appropriate information about how and when they will hear the result of repeat tests.
9. After being informed of the need for a second blood spot by the screening laboratory, the
designated maternity screening lead for that area is responsible for notifying the
appropriate health professional and ensuring that the second blood spot sample is taken as
a matter of urgency. In the case of second blood samples for initially borderline results (as
defined above) this should be no sooner than one week from the date of the original blood
spot sample.
10. The result of the second blood spot sample should be available within 2-4 working days of
receipt by the screening laboratory and, if the TSH concentration is greater than or equal to
10mU/l whole blood, the screening result should be considered positive.
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7.3 Results from the evidence review
Sixteen papers described aspects of test performance using, as the screening test, a TSH assay on
the newborn bloodspot taken at 3-8 days of age. These papers described a range of practice in
different countries and during different periods.
It was common practice to use both a borderline cut-off and a positive cut-off value for the TSH
assay results. Children whose first bloodspot TSH was above the positive cut-off were recalled for
diagnostic confirmatory testing. For children whose bloodspot TSH was higher than the borderline
cut-off but below the positive cut-off, a repeat test was usually undertaken on the same bloodspot
sample before requesting a new blood test or alerting the family, however sometimes a new sample
was requested at the same time as repeating the test on the original sample. Children were usually
only recalled for diagnostic testing if they had a borderline or positive value on the repeat test.
Many studies described results of screening at stage E, without clarifying the proportion of children
who reached this stage after an initial positive or borderline result at B. The methods for the repeat
screening test procedure (blue shaded area of Figure 2) varied by programme, with some repeating
the screening test on the original bloodspot sample and others requesting a new sample for testing.
Some children who were defined as having CHT (true positives) at stage D underwent further
evaluation at a later time point and were subsequently defined as transient CHT (stage E). The
heterogeneity between screening protocols was marked between countries and over time, thus
presenting considerable difficulty in estimating test performance at different cut-off levels.
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Figure 2: Overview of screening procedures most commonly described
In Table 2, papers which provided information about test performance are grouped by cut-off values
used to define a positive screening result on TSH assay (whole blood). For papers that defined a
borderline screening result after the initial test, the borderline cut-off values are also presented.
Four of the papers included in Table 27-10 either did not fully report screening test performance or
contained insufficient information for sensitivity, specificity and positive predictive values to be
calculated. Further discussion of the findings of these papers is therefore limited to the 13 papers
with adequate data for these estimations.
A Bloodspot
B Initial test
Positive
Borderline
D Repeat test
E Recalled for diagnostic tests
Positive
Borderline
F Re-evaluated
Negative Negative
CHTNot CHT
CHTTransient CHT
C Second bloodspot
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Table 2: Screen positive cut-off values in papers describing test performance
POSITIVE
cut-off
value
Author Country Year of
publication
Age at
bloodspot
Test method BORDERLINE
cut-off value
≥8mU/l
Nakamizo9* Japan 2007 4-6 days Enzyme-linked
immunoabsorbent assay
-
≥15mU/l
Gjurkova8* Macedonia 2008 2-5 days DELFIA -
≥17mU/l
Hopfner11 Germany 2005 3 days Corning radiolabelled -
≥20mU/l
Pharoah12 UK 1992 5-8 days Not stated ≥5mU/l
Law13 Wales 1998 7 days Immunoradiometric
assay
-
Korada7* UK 2008 6 days DELFIA ≥6mU/l
Korada14 UK 2010 6 days DELFIA ≥6mU/l
≥25mU/l
Hummer15 Denmark 1982 5 days Double antibody RIA -
Foo16 N. Ireland 2002 6-8 days 1983-86 Pharmacia
1986 DELFIA
≥10mU/l
Jones17 Scotland 2006 6-7 days 1994 IRMA (IDS)
2002 DELFIA
≥8mU/l
≥40mU/l
Dockeray18 Ireland 1980 4-5 days Pharmacia, Uppsala
RIA
≥20mU/l
Ray19 Scotland 1997 7 days 1979-82Corning
radiolab.
1982-89 polyclonal Ab
1989-93 IRMA (IDS)
≥25mU/l
Corbetta20 Italy 2009 3-4 days AutoDELFIA ≥10mU/l
≥50mU/l
Gruters21 Germany 1983 5 days Lab-specific RIA ≥20mU/l
Ilicki22 Sweden 1988 5 days Not stated -
Pettersen10* Norway 1995 newborn Before 1988 Radiolabel.
1988 DELFIA
≥15mU/l
*Insufficient data to calculate (or verify reported) test performance.
Using information from 12 papers which provided sufficient data, the sensitivity, specificity, positive
predictive value (PPV) and false positive rate (FPR) for the screening test were calculated. Within the
group of children who had false positive (FP)screening results were (1) those who were found on
diagnostic tests not to have CHT despite a positive screening results, and (2) those who were
recognised after a period of treatment to have transient CHT. Test performance was calculated after
assuming only those who were negative at diagnostic testing to be FP. If transient CHT was
evaluated, this is noted in Table 3B. Where possible, the proportion of all those screened who had (i)
a repeat screening test on the same bloodspot (Figure 1, A and D), (ii) a repeat screening test on a
new bloodspot (Figure 1, C and D), or (iii) were recalled for diagnostic confirmation (Figure 1, E) is
provided in Table 3B.
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Box 4: Calculating screening test performance
Disease Test performance:
Sc
re
en
in
g
te
st
re
su
lts yes no total
Sensitivity = TP/(TP+FN)
Specificity = TN/(FP+TN)
Positive predictive value (PPV) =
TP/(TP+FP)
False positive ratio = FP/total
screened
positive True positive
(TP)
False
positive (FP)
TP+FP
negative False negative
(FN)
True
negative
(TN)
FN+TN
total TP+FN FP+TN Total screened
The information provided by each of the 12 studies is presented in Tables 3A and 3B below. Only
three studies used a single cut-off without a borderline (Table 3A). Hummer15 tested T4 levels on
bloodspots with TSH>25mU/l before repeating the TSH assay and findings from this complex testing
process cannot be directly compared with other studies. Despite a higher cut-off, the sensitivity and
specificity of Ilicki’s22 screening test was similar to Law13, whilst the PPV (proportion of children with
a positive screen who have CHT) described by Ilicki was lower. As Law’s study is based on a larger
population, provides greater detail of test performance and is higher quality, results are likely to be
more reliable.
Test performance within the remaining nine papers is presented in Table 3B; these studies used a
borderline and a positive cut-off level. After a borderline result, the TSH assay was repeated on the
same bloodspot sample (except two studies12 20 which used a second bloodspot sample). A positive
screening test was either two results above the borderline or one result above the positive cut-off
level.
Population coverage (percentage of newborns screened), reported in three papers was 97% or over
in the most recent years studied. Only two studies12 19 described actively identifying ‘missed cases’
or late diagnoses (false negative [FN]) using multiple sources; these suggest that there may be one
FN screening result for every 200,000 to 300,000 babies screened. FN results are likely to be
underestimated by most investigators as there were no procedures for following up negative
screening results. Consequently, studies are likely to overestimate sensitivity. The lowest sensitivity
at any cut-off level was 95%, suggesting the TSH newborn bloodspot assay is sensitive whether a
borderline or single positive cut-off is used. The specificity of the TSH assay across all cut-off levels
was above 99%.
Most variation between studies was in the proportion of children whose bloodspot was re-tested or
who were recalled for diagnostic tests, and PPV. Studies in Table 3B are arranged in order of
ascending cut-off level, thus Korada14 and Pharoah12 have low cut-off levels but only around 30% of
children who have a positive screen are diagnosed with CHT. At higher cut-off levels, the PPV rises to
60-70%, similar to that estimated by Law using a single positive cut-off of 20mU/l. Exceptions to this,
e.g. Dockeray18 and Corbetta20, may be related to differences in screening procedures.
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Table 3A: Screen positive cut-off values in papers describing test performance
Author Total
screened
Coverage Sampling process TSH
cut-
off
TP FP FN TN Sensitivity Specificity PPV FPR
Results from a single assay
Law13 445,902 99.8% Used cut-off of >20mU/l for referral for
diagnostic tests. Test performance
results provided for positive screen
(defined as single result >20mU/l).
>20 136 49 0 445,717 100.00% 99.99% 73.51% 0.01%
Ilicki22 188,340 99.8% Used cut-off of >50mU/l for referral for
diagnostic tests. Test performance
results provided for positive screen
(defined as single result >50mU/l).
>50 68 50 0 188,222 100.00% 99.97% 57.63% 0.03%
Hummer15 127,111
(126,966)*
- Used cut-off of >25mU/l and tested T4
on same sample; if T4 normal
(>45nmo/l), then repeated TSH on
same sample. Test performance results
calculated for initial TSH assay.
- 32 785 1 126,294 96.97% 99.38% 3.92% 0.62%
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Table 3B: Screen positive cut-off values in papers describing test performance
Author Totalscreened
Coverag
e Sampling process TP FP FN TN Sensitivity Specificity PPV FPR
Results from combined assays (e.g. repeated screening tests for borderline
samples)
Double
screen
Korada14 63,208 - Used cut-off of 6mU/l and repeated screen
on same sample. If two results 6mU/l or
first result >20mU/l, then referred for
diagnostic confirmation. Test performance
estimated for positive screen (defined as
two results 6mU/l or one result >20mU/l).
n=98 33 87 0 63,088 100.00% 99.86% 27.50% 0.14%
Pharoah12 193,226 85%-97%§ Used cut-off of >5mU/l and repeated screen
on same sample, then requested new
sample and tested again. Test performance
results provided for positive screen (defined
as three results >5mU/l or one result
>20mU/l).
60 162 2‡ 193,002 96.77% 99.92% 27.03% 0.08%
Jones17 561,833 - Used cut-off of 8-24mU/l for repeating
screen on same sample, or 25mU/l for
referral for diagnostic testing. Test
performance results provided for positive
screen (defined as two results 8mU/l or
one result 25mU/l).
158 92 0 561,864 100.00% 99.98% 63.20% 0.02%
Foo16 (295,670)† - Used cut-off of 10-25mU/l for repeating
screen on same sample, or >25mU/l for
referral for diagnostic testing. Test
performance results provided for positive
screen (defined as two results 10mU/l or
one result >25mU/l).
85 46 0 295,539 100.00% 99.98% 64.89% 0.02%
Hopfner11 298,175 99.1% Used cut-off of 17mU/l and repeated
screen on same sample. Test performance
results provided for 129 positive screens
(defined as two results 17mU/l).
All 17 90 39 0 298,046 100.00% 99.99% 69.77% 0.01%
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Table 3B (continued): Screen positive cut-off values in papers describing test performance
Author Total
screened
Coverage Sampling process TP FP FN TN Sensitivity Specificity PPV FPR
Ray 11 992,709 - Used cut-off of 15-40mU/l for repeating
screen on same sample, or >40mU/l for
referral for diagnostic testing. Test
performance results provided for positive
screen (defined as two results 15mU/l or
one result >40mU/l).
0.01% 234 108 3‡ 992,864 98.7n3% 99.99% 68.42% 0.01%
Dockeray 18 76,224 - Used cut-off of >20-40mU/l for repeating
screen on same sample, or >40mU/l for
referral for diagnostic testing. Test
performance results provided for positive
screen (defined as two results >20mU/l or one
result >40mU/l).
19 31 1 76,174 95.00% 99.96% 38.00% 0.04%
Gruters 21 63,200 98.0% Used cut-off of 20-50mU/l for repeating
screen on same sample, or >50mU/l for
referral for diagnostic testing. Test
performance results provided for positive
screen (defined as two results 20mU/l or
one result >50mU/l).
0.37% 25 7 1 63,167 96.15% 99.99% 78.13% 0.01%
Corbetta 20 629,042 - All bloodspots >97.5% centile were repeated
on same sample. If second test was:
(1)<99% centile (<10-12mU/l), no further
testing;
(2)10-20mU/l – new bloodspot, 5mU/l
referred;
(3)20-40mU/l – new bloodspot/serum test,
referred if 5 (bloodspot) or 10 (serum);
(4)>50mU/l referred for diagnostic testing;
Test performance results provided for positive
screen (defined as three results >10mU/l or
one result >40mU/l).
1.71% 435# 578 0 627,989 100.00% 99.91% 42.95% 0.09%
* Total screened after removal of invalid screens due to technical problem; † Total newborns during period – coverage not provided; § Variability over period of study; ΐ ZĞůŝĂďůĞĨĂůƐĞŶĞŐĂƟǀ ĞĐŽƵŶƚ
as traced through multiple sources; # includes 53 cases considered true CHT after diagnostic testing but later re-evaluated and found to be transient; if transient cases are considered false positive,
then sensitivity=100.00%, specificity=99.90%, PPV=37.72% and FPR=0.10%.
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Using the information provided within most papers, it is difficult to estimate the impact of
having a borderline cut-off level on the frequency of repeat testing. However results from the
studies by Ray19 and Jones17 are presented in Table 4 and demonstrate that, with the decrease in
cut-off levels, there was an increase in the total number of screening test samples processed as
a percentage of the total number of children screened. This suggests that there was an increase
in the number of children who had a repeat test. If the repeat test was undertaken on the
original sample, this would have implications for the volume of work in the laboratory and for
the timeliness of screening test results, but would not result in an additional contact with the
family.
Table 4: Increase in numbers of additional TSH assays required (repeated on same bloodspot)
as borderline cut-off decreases (taken from Ray19 and Jones17)
Time period Initial test Repeat test
Borderline cut-off (mU/L) extra (repeat tests) as % all children tested
1980-82 >25-50 1,180 0.58%
1983-89 >15-40 4,135 0.90%
1990-01 >10-40 14,725 2.04%
2002-03 >8-25 18,330 17.68%
False negative results
Leger23 assessed ‘missed’ cases or false negative screen results in the first nine years of the
French newborn screening programme, during which over 6,000,000 infants were screened and
1,742 infants diagnosed with CHT. Of 50 cases not detected by screening and diagnosed
clinically between ages 7 days and 5 years 2 months, 27 were missed due to samples not being
taken, being lost en-route to the laboratory or being mis-read in the laboratory, whilst 23 were
re-evaluated and found to be negative on the original bloodspot also. Leger noted that less false
negatives occurred in more recent years of the programme, however it is unclear if follow-up
was sufficiently long to verify this.
Psychological impact of false positive results
Two studies considered the impact on parents of a false positive screening result.6 24 the
majority of families had strong emotional reactions at the time of finding out that the screening
result was a false positive, but insecurity about their child’s health persisted only in a minority
beyond one year of age.24 In the longer-term, the child-parent relationship was affected in some
families up to 4 years of age.6 It is likely that additional family and coping factors may influence
the persistence of problems.
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7.4 Interpretation of the published evidence
Evidence from the literature review suggested that the sensitivity and specificity of the TSH
assay is high and that these do not differ markedly if either a single screening cut-off level of
around 20mU/l or borderline cut-offs from 5-20mU/l are combined with positive cut-off levels of
20-50mU/l. As most screening programmes did not actively seek ‘missed cases’, false negative
rates presented by most studies are likely to be underestimated and Leger suggests up to five
cases per year could be missed. The PPV varies with TSH cut-off level and is best with either a
single positive cut-off of around 20mU/l or borderline cut-off levels over 10mU/l. When
borderline cut-off levels are below 10mU/l, the number of repeat tests increases markedly with
implications for laboratory workload and timeliness.
Members of the test performance subgroup considered that all published evidence, except for
Corbetta’s study, was based on laboratory methods no longer in use, and therefore the cut-off
values used could not be applied to current UK laboratories which universally employ
AutoDELFIA methods. The published evidence was not considered adequate to support a
specific cut-off threshold.
7.5 Additional evidence relating to development of the 2005 standards
A review of laboratory TSH test thresholds was undertaken in 2004 to inform the 2005
standards. Written reports indicated that, in 2004:
• 11 laboratories were using Autodelfia and one manual Delfia methods
• Presumptive negative cut-offs were <6 to <13 (4 used <8 and 4 used <10) mU/L in whole
blood
• Borderline cut-offs were >6 to <30 (2 used <19; 2 used <20; 2 used <25) mU/L in whole
blood
• Presumptive positive cut-off was >20 mU/L in whole blood
• It was recognised that regional variance in thresholds may be due to genetics or iodine
deficiency and that these should be mapped
• A consensus was reached that national cut-offs should be: <10mU/L=negative, ≥11-
20mU/L=borderline, >20mU/L=positive. This consensus was based on the fact that these
values were in keeping with the majority of contemporary reference ranges and would
establish uniformity across the UK.
 EWG members concluded that the cut-off values in the 2005 standards were established by a
consensus of expert opinion.
7.6 Great Ormond St Hospital ‘Borderline Study’ 2011
Dr Catherine Peters and Ms Shirley Langham provided original data from a study at Great
Ormond St (GOS) Hospital, which aimed to follow-up outcomes in children who had been
diagnosed with CHT after two borderline (TSH ≥6mU/L and <10mU/L on bloodspot) screening 
test results. Using this dataset, which included the bloodspot TSH values of 223,658 newborns
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screened at GOS, the number of children who would require a repeat bloodspot and further
investigation were compared for borderline cut-off thresholds of 6mU/L and 10mU/L (Figure 3).
Figure 3: GOS borderline study data – comparison of cut-off thresholds
Key: bold text=number of children; italics=TSH cut-off level; Screen results - true positive (TP), false
positive (FP), true negative (TN), false negative (FN)
Cut-off: ≥10mU/L to <20mU/L
Cut-off: ≥6mU/L to <20mU/L 
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Box 5: Assumptions made in estimating test performance using the GOS study data
True Positive (TP) – starting treatment after a positive result on diagnostic investigation indicates that the
child has a confirmed diagnosis of CHT. It is possible that some of these children do not continue
treatment lifelong.
False Positive (FP) – children who have repeated positive screening results but do not start treatment
after diagnostic investigations. It is possible that starting treatment is also dependent on clinician
variation, or that some children start treatment later in life.
True Negatives (TN) – children who have a negative initial bloodspot, or who have an initial positive
screening bloodspot then a second negative bloodspot. If children are not followed up to determine if
there are any ‘missed’ cases (or False Negatives [FN]), all will be assumed to be true negatives.
Using the GOS study data, Figure 3 compares the number of children who would be referred for
investigation with presumed positive screening test results when the cut-off is TSH>6mU/L with
>10mU/L. Children who are treated with levothyroxine after diagnostic testing are deemed to be
true cases (either true positive or false negative results of screening). As children with negative
screening test results were not followed up, they are all assumed to be ‘true negatives’,
however there may be missed cases of CHT within this group. Of the 223,658 children screened
between January 2006 and December 2007 by the GOS laboratory, 170 had a TSH result on or
above 10mU/L and were referred for further testing. Of these, 30 were referred for diagnostic
investigation and 18 were given treatment. Using the cut-off of ≥6mU/L, 658 children would 
have required re-testing, of which 74 were referred for diagnostic investigation and 46 given
treatment.
Table 5: Test performance estimates using data from GOS borderline study
Cut-off TSH TP FP TN FN sensitivity specificity PPV FP rate
≥10 mU/L 107 16 223,535 0 100.00% 99.99% 86.99% 0.01%
≥6 mU/L 135 32 223,491 0 100.00% 99.99% 80.84% 0.01%
Key: True positive (TP), false positive (FP), true negative (TN), false negative (FN), positive predictive value (PPV)
Test performance estimated using GOS study data was compared with three published studies
using Delfia laboratory screening methods (see Table 6 below):
 The GOS study dataset, using the Autodelfia method, provided the best direct comparison of
cut-off levels and demonstrated that, whilst sensitivity and specificity did not alter, the PPV
was higher for a cut-off of 10mU/L than 6mU/L. However, outcomes were based on
commencement of treatment immediately after diagnostic testing therefore permanence or
severity of CHT diagnoses could not be assessed.
 The EWG concluded that sensitivity and specificity was similar when the upper cut-off is 20-
25mU/L and lower cut-off is 5-10mU/L using either testing method.
 EWG members considered that this would support an upper cut-off value of 20mU/L.
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 Some studies suggested that the false positive rate was 4-7 times higher and PPV was halved
when lower cut-offs of 5-6mU/L - 20mU/L were used compared with cut-off of 8-10mU/L -
25mU/L, however EWG members felt that lower and upper limits should not be viewed
separately using these data as laboratories often adjusted the range as a whole.
Table 6: Comparing screening test performance for three studies using Delfia methods with
the Great Ormond St study dataset:
Number Sensitivity Specificity PPV FP rate
6mU/L – 20mU/L
Korada 2010 Delfia 63,000 100.0% 99.9% 27.5% 0.14%
8mU/L – 25mU/L
Jones 2006 Delfia 562,000 100.0% 99.9% 63.2% 0.02%
10mU/L – 25mU/L
Foo 2002 Delfia 296,000 100.0% 99.9% 64.9% 0.02%
10mU/L – 20mU/L
GOSH study 2007 Autodelfia 223,658 100.0% 99.9% 87.0% 0.01%
6mU/L – 20mU/L
GOSH study 2007 Autodelfia 223,658 100.0% 99.9% 80.8% 0.01%
7.7 Additional evidence relating to long-term outcomes and late
diagnoses
Cognitive outcomes in unscreened populations
Grosse and Van Vliet’s paper (2011) reviewed population-based studies which measured
cognitive test scores in children with clinically diagnosed CHT born prior to the introduction of
newborn screening.25 The authors found that the prevalence of CHT increased from 1 in 6,500
before the introduction of screening to 1 in 3,000 after, suggesting that screening might have
led to increased detection of milder CHT cases that were not previously recognised clinically (i.e.
subclinical cases). In four studies of children with clinically diagnosed CHT, 8-28% had
intellectual disability (IQ <70) and the mean IQ was 85 (minus 1 SD). Among children with
subclinical CHT, the risk of overt intellectual disability was lower than previously estimated but
IQ appeared to be reduced by on average seven points and increased behavioural abnormalities
were documented.
 As a screening threshold for TSH of 10mU/L may already detect around twice as many cases
as would become apparent clinically in an unscreened population, the EWG did not consider
this sufficient evidence to support lowering the cut-off.
Final Report (January 2013) 33 | Page
Economic effects of late diagnosis
The economic effects of seven points loss of IQ for an individual child was reviewed in the
literature relating to environmental lead exposure and effects on IQ. Two sources estimated the
lifetime economic effect, in earnings lost, of a reduction in childhood IQ of seven points:
• £23,800 across the lifetime
Source: Dr Gul IZMIR, 1993 NSW EPA, reference: "Interdepartmental Lead Taskforce: New South Wales Lead
Management Action Plan. Background Papers" Publ. NSW EPA 1994. Accessed at
http://www.lead.org.au/lanv5n3/lan5n3-4.html on 17-06-2011. (1 point = £3,400; at exchange rate £1 = AU$ 1.53)
• £9,527- £41,580 across the lifetime
Source: President’s Task Force on Environmental Health Risks and Safety Risks to Children, Eliminating Childhood Lead
Poisoning: A Federal Strategy Targeting Lead Paint Hazards, February 2000, pA-26. Accessed on 17-06-2011 at
http://yosemite.epa.gov/ochp/ochpweb.nsf/content/leadhaz.htm/$file/leadhaz.pdf (1 point = £1,360-£5,940; at
exchange rate £1 = US$ 1.62)
Long-term outcomes and permanence of CHT
Published evidence about later cognitive outcomes related to different screening cut-off levels
was noted by the EWG to be limited, highlighting the need for longer-term outcome studies with
a particular focus on transient or mild hypothyroidism.26 27
 EWG members concluded that test cut-off levels could only be considered in relation to
the outcomes of confirmatory diagnostic test results and investigations of transience of
CHT at 2-3 years of age.
Studies of longer-term outcomes did not always describe a ‘withdrawal’ or ‘trial off-therapy’ to
confirm permanence of CHT at 2-3 years of age.28 Outcomes after newborn screening were
often described only up to diagnostic confirmation or the initiation of treatment.
 EWG members noted that, as a ‘trial off-therapy’ to confirm permanent CHT often did
not occur within the first three years of life, ICR standards should provide guidance as to
when a ‘trial off-therapy’ is warranted.
7.8 EWG Final Recommendations and Revised Standards relating to
Screening Test Performance
Generic standards:
The expert working group (EWG) considered that some standards should be regarded as
generic, i.e. applying across all screening programmes and need not be repeated within the
standards specific to CHT. Standards which on this basis could be removed included:
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Standard 3 (2005): Collection and assay of the bloodspot sample should not be delayed in
premature infants for whom it should be repeated when the baby attains the equivalent of 36
weeks gestation. Similarly it should not be delayed in babies who receive a blood transfusion for
whom the sample should be repeated 72 hours later.
• The EWG considered that standards for preterm babies and blood transfusion were
covered elsewhere in the standards and should not be repeated in the congenital hypothyroidism
(CHT)-specific screening standards.
Standard 7 (2005): ‘This second blood spot sample should be taken by a midwife or, if the baby
is still in hospital, by the clinician responsible for their clinical care.
• The EWG considered that this standard should be covered in generic standards about
responsibility for taking second blood spots. They recommended deletion from CHT-specific
screening standards.
Standard 8 (2005): Parents of babies with borderline results, irrespective of whether the baby is
at home or in hospital, should be informed of the reason for a second blood spot sample and
given appropriate information about how and when they will hear the result of repeat tests.
• The EWG considered that this standard should be covered in generic standards about
responsibility for taking second blood spots. They recommended deletion from CHT-specific
screening standards.
Standard 9 (2005): After being informed of the need for a second blood spot by the screening
laboratory, the designated maternity screening lead for that area is responsible for notifying the
appropriate health professional and ensuring that the second blood spot sample is taken as a
matter of urgency. In the case of the second blood spot samples for initially borderline results
(as defined above) this should be no sooner than one week from the date of the original blood
spot sample.
• The EWG considered that the first statement in this standard should be covered in
generic standards about responsibility for taking repeat blood spots. The second statement is
now covered by the revised standard 4. Members recommended deletion of this standard from
the CHT-specific screening standards.
Standard 10 (2005): The result of the second blood spot sample should be available within 2-4
working days of receipt by the screening laboratory and, if the TSH concentration is greater than
or equal to 10mU/L whole blood, the screening result should be considered positive.
• The EWG considered that this standard should be covered by new standard 3 which
defines the positive cut-off for a presumed positive screening test and the need for referral. The
time period for laboratories to report tests should be covered by new standard 1. Members
therefore recommended deletion of this standard.
Final Report (January 2013) 35 | Page
Newborn blood spot testing pathway
EWG members acknowledged that previous guidelines were unclear about the procedure to be
followed for testing blood spots. A standard pathway for blood spot testing as agreed and a flow
diagram developed for guidance (see Section 2 for the Screening Protocol flow diagram).
New headings were proposed for each section of the standards relating to testing:
• Section 1 heading: ‘The screening protocol’
• Section 2 heading: ‘Categorisation of initial screen result’
• Section 3 heading: ‘Borderline screen result’
Standards relating to the testing pathway were amended to comply with the standard testing
pathway:
Section 1: The screening protocol
 To maintain consistency with standards for other conditions, a new additional standard was
proposed (new Standard 1). Details of the analytical cut-off and laboratory test process were
included in this standard:
New Standard 1 The initial screening sample (not included in 2005 standards):
TSH analysis is performed on a single spot from the initial dried blood sample.
Samples with TSH ≥ a preliminary threshold (analytical cut-off*) of 8 mU/l whole blood (WB) are 
retested in duplicate from the same card but a different spot(s). Action is taken on the triplicate
mean result.
Second sample – TSH is analysed in duplicate and action taken on duplicate result.
Timeliness of analysis – analysis is timed to permit referral of screen positive results within 2-4
working days of sample receipt.
*The analytical cut-off is set at 20% below the screen action cut-off of 10mU/L WB to allow for
natural variation in the TSH assay (i.e. the coefficient of variation, CV=10%) and to minimise the
effect of volumetric variability that occurs in dried blood spots. Re-testing also acts as
confirmation of correct sample identification.
Section 2: Categorisation of initial screen result
 The EWG recommended that Standards 1-3 (2005) became standards 2-4 in the new version
and are re-ordered so that negative, then positive, then borderline test results are defined.
 EWG members reviewed the evidence for changing the cut-off level and concluded that there
was insufficient evidence, in particular using the Autodelfia process, to support defining a
new cut-off level. The cut-off level defined in the new standards was therefore not altered
from previous standards.
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New Standard 2. Babies in whom the TSH concentration is <10mU/L whole blood in the initial
screening sample should be considered to have a negative screening result for CHT
Report CHT not suspected.
New Standard 3. Babies in whom the TSH concentration is ≥20mU/L whole blood on the initial 
screening sample should be considered to have a positive screening result for CHT
Report and refer CHT suspected.
New Standard 4. Babies in whom the TSH concentration is ≥10mU/L and <20mU/L whole blood 
on the initial screening sample should be considered to have a borderline result for CHT.
Section 3: Borderline screen result
 Standards 4-6 (2005): These should become standards 5-7 in the new version and they define
the actions to be taken after a borderline test result.
New Standard 5. On detecting a borderline result a second blood spot sample is to be taken 7-
10 days after the initial sample.1
 EWG members considered it important to recommend a period of at least 7 days delay to
allow normal stabilisation of TSH levels in newborns before taking a second blood spot
sample.
New Standard 6. If the TSH concentration is less than <10mU/L whole blood in this second
sample, the baby should be considered to have a negative screening result for CHT.
Report CHT not suspected
New Standard 7. If the TSH concentration is ≥10mU/L whole blood in this second assay, the 
baby should be referred.
Report and refer as CHT suspected.
7.9 Recommendations for further research
Across the UK, screening laboratories use varying TSH assay thresholds as the cut-off to define
positive and borderline screening results. EWG members also noted the lack of studies with
long-term population follow-up to determine false negative (missed) and transient CHT cases,
necessary to evaluate screening test performance with Autodelfia. EWG members highlighted
the need for further research to define optimum cut-off thresholds for the TSH assay that could
be applied nationally.
1 The working group proposed the wording of the standard as ‘to be taken (as close to) but no sooner than
7 days after the initial sample’, however this was changed ‘to be taken 7-10 days after the initial sample’
after the public consultation as it was considered that delay beyond 10 days would not be optimal.
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8 Confirmatory Diagnostic Tests: Type, Timing and Association
with Outcome
8.1 Original (2005) ICR standards relevant to diagnostic tests
Children who have a positive screening result are referred for further testing to confirm or
exclude a diagnosis of CHT. The diagnostic test subgroup considered standards 16-21 and 25
from 2005 (Box 6).
EWG members drew on four sources of evidence:
• Evidence from the literature review of test performance (Olafsdottir & Knowles)
• Additional published evidence highlighted by the diagnostic test subgroup
• Data from an audit of diagnostic laboratories in Wales
• Expert evidence was considered by a subgroup consisting of a diagnostic laboratory
director, consultant radiologist, thyroid research assistant and consultant paediatric
audiologist.
Box 6: Standards 16 to 21, 25 (2005)
16. He designated clinician responsible for assessing the baby with a positive screening
result should take a clinical history and perform a clinical examination.
17. Diagnostic tests considered essential are:
a. Free T4 (plasma or serum)
b. TSH (plasma or serum)
18. Diagnosis using Free T4 should be performed on a plasma or serum sample using the
appropriate age-related reference range as defined by the laboratory in relation to the
equipment used.
19. Clinicians may, using appropriate imaging techniques, investigate whether the thyroid
gland is:
a. Normally situated
b. Of a normal size
c. Of a normal shape
d. Present at all
20. In addition, the following tests may be helpful:
a. Thyroid antibodies
b. Thyroglobulin (if the radiological imaging indicated that there is no thyroid
present, thyroglobulin analysis should be requested)
21. The following tests may be performed on the mother to aid diagnosis:
a. Thyroid antibodies
b. TSH
c. Free T4
25. Once treatment has been started, a baby should be reviewed, with a blood test at each
visit. The timing of such visits may vary according to local circumstances but it is
suggested should occur at 2 weeks, 6 weeks, 3 months, 6 months, 12 months after
treatment is started, and thereafter as indicated, with management complying with
BSPED recommendations for interpretation of tests and dosage. Visits may occur more
frequently as necessary.
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8.2 Results from the evidence review
Within the literature review, published studies describing the process of diagnostic confirmation
were examined to assess the:
 timing of the diagnostic confirmatory testing
 range of tests undertaken at the time of establishing diagnosis
 purpose of undertaking each test.
Particular issues which were addressed were whether repeat screening after a borderline result
might delay diagnostic testing, the timing of treatment onset after diagnostic testing, and
discriminating between permanent and transient CHT.
Eighty-nine papers were reviewed which described some or all of the tests used for diagnostic
confirmation of CHT in infants with a positive screening result. The screening test in 56 studies
was a TSH assay on the newborn bloodspot, however the cut-off levels for a borderline or
positive test varied or were not defined. The remaining studies used bloodspot T4 assay instead
of, or in addition to TSH assay (n=8; Netherlands, Italy and US), or did not specify the screening
test. Due to the heterogeneity of newborn screening procedures, no attempt was made to
relate confirmatory diagnostic tests to the screening test used.
Timing of tests for diagnostic confirmation
The age at which diagnostic tests were undertaken varied between studies, however the mean
(and/or median) age ranged from 10 to 27 days in most studies, thus most diagnostic testing
took place during the second to fourth weeks of life. Diagnostic tests were normally undertaken
prior to treatment, but some authors noted that thyroid scans might also be undertaken at a
later age, in particular during a trial withdrawal of treatment to confirm permanence of CHT at
2-3 years of age.
In most studies, confirmatory tests were performed between birth and 60 days of age and most
frequently included serum TSH, T4 and triiodothyronine (T3) levels and thyroid radioisotope
scans (scintigraphy).
Clinical examination (CE) was performed at a mean 10-15 days, whilst neck ultrasound (US),
serum thyroid binding globulin (TBG) and serum thyroglobulin (Tg) levels were assessed
between 10 and 23 days of life. Evaluation of skeletal maturity (bone age) was more likely to
occur after two weeks of age (in studies where the timing was specified).
In one study by Mathai29, diagnostic testing varied by screening test result; diagnostic testing
took place at a mean of 2-3 days of age if the first screening result was positive but was delayed
until day 14 for children whose first screen was borderline as repeat screening tests were
performed. No other studies directly compared the timing of diagnostic testing after positive
and borderline screen results. Although Law13 and Hummer15 employed a single cut-off result,
without repeat screens, diagnostic testing took place at a mean of 15 and 26 days respectively.
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Table 7: Timing of diagnostic testing
Timing of diagnostic tests Studies reporting testing at this age
1st week of life (0-7 days) Alvarez30 (Day [D.] 1), Mathai29 (D. 2-3 if positive screen),
Dubuis31 (D. 3-14)
2nd week (8-14 days) Dimitropoulos32/Glorieux33 (D. 9),
Corbetta20/Jones17/Ray19/ Bakker34/Dockeray18/Korada7
14/Connelly35 (D. 10-13), Campos36/Kohler37 (D. 14),
Mathai29 (D. 14 if borderline screen result)
3rd week (15-21 days) Law13 (D. 15), Gunn38/Heyerdahl39/Tillotson40/Oerbeck41 42
(D. 17), Toublanc43 (D. 17-20), Gjurkova8 (D. 19), Newland44
(D. 21)
4th week (22-28 days) Salerno45-49 (D. 21-26), Niu50 (D. 22-23), Hummer15 (D. 26),
Delvecchio51 (D. 27), Fisher52 (D. 24-50)
Whilst some authors listed all tests undertaken, others only highlighted the tests that were
relevant to their study findings. In Table 8, the number of papers describing each test and the
purpose of each test is summarised. The tests mentioned most often were serum TSH and T4
estimations, measurement of bone age and thyroid scintigraphy.
Table 8: Diagnostic tests described by different studies
Diagnostic test Number of
studies using
test
Purpose of the test
TSH Serum 66 Confirm the diagnosis
Assess severity
T4 Serum 66
Triiodothyronine [T3] Serum 21
Thyroglobulin [Tg] Serum 5
Thyroid binding globulin [TBG] Serum 2
Low molecular weight iodopeptides Not stated 1
Urinary iodides Urine 2
Clinical examination Signs of CHT 8 Assess severity
Length, weight & head circumference 2
Clinical photo 1
Thyroid scintigraphy/radioisotope scan 123Iodine 18 Identify aetiology
Assess severity99Technetium 27
Neck ultrasound 7
Bone age Knee X-ray 34 Assess severity
Knee & foot X-ray 1
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Purpose of tests performed at the time of diagnosis
The purposes for which tests were undertaken at the time of diagnosis were:
 To confirm/exclude the diagnosis of CHT in children with a positive newborn screening
result
And in children in whom the diagnosis was confirmed, to:
 Define the presence or absence of thyroid tissue (and thus the aetiology)
 Assess the severity of CHT
 Guide initiation of treatment with replacement therapy
 Predict later outcomes.
Serum and urinary hormone tests were described as confirming the diagnosis, including serum
TSH, T4, T3, TBG, Tg and urine iodide excretion.
Thyroid scans, either using radio-isotopes (scintigraphy) or neck ultrasound, were described as
determining ‘aetiology’, through determining the absence of thyroid tissue or presence of a
partial thyroid or ectopic thyroid tissue.
Serum and urinary hormone estimations, thyroid scans, bone age estimation and clinical
examination (for symptoms and signs of CHT) were all described as defining the severity of the
CHT. In the majority of studies ‘severity’ was defined by aetiology, thus absence of a thyroid
gland was deemed most severe. However, some authors defined severity by a low level of
serum T4 or a greater delay in bone maturity at the time of diagnosis.
Variation in test methods described
There was heterogeneity across studies in the test methods used, in particular for evaluating
skeletal maturity (bone age) or the presence of thyroid tissue.
Most bone age assessments appeared to measure femoral epiphyseal development in a knee
joint X-ray (Table 9).
Table 9: Methods for skeletal maturity (bone age) assessment:
Bone maturity test method Reference
Greulich & Pyle (knee or knee/foot comparison) Salerno et al (1999)46
Salerno et al (2001)47
Salerno et al (2002)45
Heyerdahl et al (1996)53
Hulse et al (1982)54
Kuhns and Finnstrom (knee) Germak (1990)55
Salerno et al (2002)45
Senecal (knee) Moschini et al (1986)56
Newland et al (1991)44
Von Harnack (knee) Newland et al (1991)44
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Table 10: Type of thyroid scan used
Type of Thyroid Scan Study references
Technetium scans (99mTc) scans Alvarez (2010)57
(27 studies) Battisti (1996)58
Connelly (2001)35
Costa (1998)59
Delvecchio (2007)51
Dockeray (1980)18
Dubuis (1996)31
Gruters (1983)21
Gunn (1996)38
Heyerdahl (1991)60
Jones (2006)17
Leger (2001)61
Mathai (2008)29
Moschini (1986)56
Niu (2004)50
Oerbeck (2003)42; Oerbeck (2005)41
Rovet (1992)62; Rovet (1996b)63; Rovet (1999)64; Rovet (2000a)65;
Rovet (2005)66;
Salerno (1999)46; Salerno (1999)46; Salerno (2002)45; Salerno
(2004)48
Winkler (1993)67
Iodide-123 (123I) scan Bakker (2002)34
(18 studies) Corbetta (2009)
Germak (1990)
Glorieux (1992)
Heyerdahl (1991)
Hopfner (2005)
Hulse (1982)
Jones (2006)
Kooistra (2004)
Leger (2001)
Murphy (1986)
Oerbeck (2003); Oerbeck (2005)
Salerno (2001); Salerno (2002); Salerno (2004)
Toublanc (1997); Toublanc (2005)
Neck ultrasound Bakker (2002)
(7 studies) Corbetta (2009)
Heyerdahl (1991)
Jones (2006)
Kooistra (2004)
Niu (2004)
Winkler (1993)
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In Table 10, studies are divided by the type of thyroid scan that was used. Some studies used
more than one type, usually because multiple centres or time periods were involved.
8.2.1 Tests which were most frequently used after a positive screening result to
confirm the diagnosis and aetiology
Serum hormone levels
All studies reported measuring serum TSH and T4 levels to enable diagnostic confirmation after
a screening result suggestive of CHT.
Thyroid scan
Sixty-two studies (of medium quality rating, M+ or M-) described a thyroid scan using either
radio-isotope scintigraphy (n=54) and/or neck ultrasound (n=10) at the time of diagnosis. Scans
were used to define three groups for comparison: children with complete absence of the thyroid
(also called agenesis, aplasia or athyreosis), those with ectopic thyroid tissue (present but in an
abnormal position) and those with dyshormonogenetic thyroid tissue (present but with abnormal
hormonal production). Perry reported that whilst thyroid scintigraphy was better overall at
defining thyroid abnormalities, ultrasound detected additional detail of gland structure that was
of importance.
Thyroid scans were not the primary method for confirming the diagnosis of CHT but evidence
from these studies suggested that children with complete absence of thyroid tissue might have a
more severe form of CHT, demonstrated through higher serum TSH or lower serum T4 levels68
and/or greater delay in bone maturation at initial diagnosis. In particular, Delvecchio and
colleagues51 found that children with an absent thyroid gland were more likely to demonstrate
delayed bone age at diagnosis than those with an ectopic thyroid or thyroid
dyshormonogenesis.
8.2.2 Association of diagnostic test results with replacement therapy
Serum hormone levels
Pre-treatment serum T4 levels at diagnosis were strongly associated with serumT4 values
measured after the onset of therapy, thus low serum T4 levels (<21nmol/L) at diagnosis were
predictive of suboptimal T4 levels one month after start of treatment.38 Delvecchio et al also
reported that serum T4 <30nmol/L at diagnosis predicted a higher dose requirement for
levothyroxine (LT4) replacement therapy to maintain normal serum hormone levels throughout
childhood and adolescence, although this difference only became statistically significant after 15
years of age.
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Thyroid scan results
Evaluation of the underlying aetiology of the CHT was often used to guide the starting dose of
replacement therapy. Absence of the thyroid was associated with the need for a higher initial
dosage of LT4.29 51 55 and more frequent dose adjustments in the first year68, compared with
children who had dyshormonogenesis. Germak55 reported that patients with
dyshormonogenesis achieved normal TSH levels more rapidly than patients with thyroid
agenesis.
Gunn and colleagues38 found that pre-treatment serum T4 values were significantly lower in
children with agenesis or dyshormonogenesis (12.9 ± 10.3nmol/l) than in those with thyroid
ectopia (51.1 ±32.9nmol/l). Moreover, Gunn reported that a T4 >26nmol/l positively predicted
ectopic thyroid tissue in 100% children. Germak55 found that serum T4 and T3 concentrations
were lower in infants with thyroid agenesis than ectopic thyroid, however this difference was
not statistically significant.
Children with thyroid dyshormonogenesis appeared to have the most favourable response to
replacement therapy. In a 12 year follow up study, Delvecchio51, found that these patients were
more likely to have their replacement therapy dose reduced during follow-up and were least
likely to require increased therapy to maintain thyroid hormone levels in the normal range.
Similarly, Mathai29 found that dyshormonogenetic patients had significantly fewer dose changes
relative to other aetiological groups. Germak55 reported that in the first months of treatment,
dyshormonogenetic patients required lower LT4 doses relative to patients with absent or
ectopic thyroid glands and normalised TSH levels quicker and Song68 noted that children with
absent thyroids were not as frequently found within their group of children who most rapidly
normalised TSH levels on treatment.
Only Mathai29 described varying the initial dose of replacement therapy based on aetiological
diagnosis. He gave children with thyroid agenesis a dose of 15µg/kg/day LT4, while patients
with ectopic thyroid received 12 µg/kg/day and dyshormonogenetic patients 10 µg/kg/day. This
was found to normalise serumT4 levels more rapidly within each group and had a lower risk of
overtreatment.
Bone age
Children with greater delay in bone age at the time of diagnosis have been reported to need
higher initial doses of LT4 supplementation45 51 and an increased frequency of changes in dosage
after initiation of therapy51, suggesting that they may represent a more severely affected group.
Only Dubuis31 has reported adjusting the initial dose of replacement therapy based on bone
maturity.
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8.2.3 Association of diagnostic tests with late outcomes
Eighteen studies reported outcomes in relation to serum T4 levels (described as T4, total T4 or
free T4) and one in relation to T3 levels at diagnosis. Of these, 12 received a quality rating of M+.
Only two studies reported outcomes in relation to TSH and one with regard to clinical
examination. The findings of studies associating late outcomes with diagnostic testing are
summarised in Table 11.
Serum hormone levels
Most studies investigating the relationship between confirmatory test results and prognosis
focused on the relationship between initial serum T4 levels and later developmental and
cognitive outcomes. Verbal and performance IQ36 46, perception, attention69, reading69,
memory69, motor42, language69 abilities and global development62 were assessed using a variety
of measures, including standardised psychometric instruments, such as the WISC-R (assessment
of IQ), McCarthy Scales of Children’s Abilities2 and Bayley Scales of Infant Development.42 46 62 70
A low initial serum T4 concentration at diagnosis was associated with poorer intellectual and
motor development scores.32 40 69 70 Whilst most studies investigated a linear relationship, three
authors described threshold values of serum T4 predictive of later outcome. Murphy and
colleagues70 found that children who had an initial T4 <20nmol/l tended to achieve lower scores
on the McCarthy Scales than those with higher initial concentrations. Tillotson and colleagues40
reported differential outcomes at a slightly higher threshold of 42.8nmol/l and initial T4 values
below this were associated with 11-12 points deficit in IQ. Rovet62 found that patients with T4 <4
µg/dl had impairment of global intellectual functioning at one year of age. A further six studies
defined severity as a specific T4 cut-off level at the time of diagnosis and explored outcomes
relative to this. Heyerdahl71 and Salerno45 both reported using T4 <40nmol/l as the cut-off for a
severe CHT diagnosis, whilst Leger61 used a cut-off value of T4<53nmol/l for a severe case of
CHT. Rovet69 defined a T4 level <4µg/dl as severe CHT. Finally, Oerbeck and colleagues42 used T4
as an index of severity, but did not report any cut-off. In each of these studies, children defined
as having ‘severe’ CHT experienced worse developmental and cognitive outcomes.
Murphy70 found that an initial serum T3 value lower than 2nmol/L was associated with poorer
scores on the McCarthy Scales.
2 The McCarthy Scales of Children’s Abilities measures the abilities of preschool children aged 2.5-8.5
years on six scales: verbal, perceptual-performance, quantitative, composite (general cognitive), memory
and motor.
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Thyroid scan results
Studies discussing outcomes in relation to thyroid scans at diagnosis generally indicated less
favourable intellectual outcomes for children with absence of the thyroid, relative to those with
ectopic thyroid tissue or dyshormonogenetic thyroid tissue.32 46 60 62 68-70 Some studies indicated a
global neurological impact for patients with thyroid agenesis32 46 62, while others indicated a
more narrow impairment, specifically related to IQ scores.60 This variability in findings may
partly have been due to differences in the instruments used for assessment and the age at
which assessments were made. Finally, children with absent thyroid were found to be at an
increased risk of late entry into the first grade of secondary school.61
The differences in cognitive outcomes were only noted between children with absent thyroids
compared with other groups, and no authors reported a difference in IQ between children with
dyshormonogenetic and ectopic thyroid glands.
Bone age
Twenty-one studies discussed outcome in relation to bone age, 15 of which received a quality
rating of M+. Bone age was measured in weeks and expected to be approximately 37 weeks at
birth or at the time of diagnosis in most studies. Leger61 defined absence of the knee epiphyseal
ossification centres as severe CHT, while Dubuis31 associated a knee epiphyses <0.05cm2 with
severe CHT.
Various studies reported worse developmental outcomes for patients with more marked delay
in bone age at diagnosis.36 60 62 69 70 This association was noted using different measures of
developmental outcomes, including the McCarthy scales70, delayed entry into the first grade of
secondary school (Leger et al, 2001), verbal IQ [VIQ] scores36, performance IQ [PIQ] scores and
visuo-spatial ability.69 Moreover, this negative relationship was evident from preschool tests up
to the age of 13 years.69
Rovet et al62 found that CHT patients with bone age ≤36weeks at birth were outperformed, on 
measures of language ability at two years of age, visuomotor skills at 3 years, motor skills at
three years and Bayley’s mental development index score at 18 months, by patients whose bone
age was >37 weeks at birth. Similarly, Campos36 found that a bone age >32 weeks gestation at
birth was associated with higher verbal IQ, and Murphy70 found that a bone age <30 weeks
gestation at birth was associated with poorer scores on the McCarthy Scales.
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Table 11: Relationship between Diagnostic Confirmatory Tests and Later Outcomes
Type of test Relation to outcomes
T4 Preschool ability scales:
Predicts performance on the McCarthy scales at 3yrs (Murphy 1986)70
Correlated with Developmental Quotient (DQ) of the Griffiths test at age 1 and 2 (Law 199813; Nakamizo 20079) Predicts development at 2 and 6 yrs
(Heyerdahl 199160).
Intelligence Quotient (IQ):
Predicts Full-Scale Intelligence Quotient (FSIQ), Performance IQ (PIQ), 3rd grade reading & arithmetic ability (Rovet 200065)
Predicts global intellectual functioning (Rovet 199262)
Predicts IQ (Salerno 199946)
Predicts IQ values below 42.8nmol/l were associated with an average deficit of 11-12 IQ points (Tillotson 199440)
Verbal IQ (VIQ) significantly higher in patients with T4 >2ng/dL (Campos 199536)
Associated with WISC-R FS score (Connelly 200135)
Predicts FSIQ, VIQ, and PIQ scores at 10yrs (Kempers 200772)
Wider cognitive skills:
Correlated with increased risk of late entry into first grade of secondary schooling (Leger 200161)
Correlates with attention, language, motor and memory skills (Rovet 199969)
Motor performance:
Predicts motor performance (Oerbeck 200342)
Behaviour:
Predicts behavioural problems in 3rd grade of schooling (Rovet 200065)
TSH Preschool ability scales:
Association with Developmental Quotient (DQ) scores (Nakamizo 20079)
Wider cognitive skills:
Predicts language performance at 18 months (Alvarez 200430)
T3 Preschool ability scales:
Predicts performance on the McCarthy scales at 3yrs (Murphy 198670)
Clinical
evaluation
Preschool ability scales:
Major clinical symptoms associated with lower DQ scores (Nakamizo 20079)
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Table 11: Relationship between Diagnostic Confirmatory Tests and Later Outcomes (continued)
Type of test Relation to outcomes
Thyroid scan Preschool ability scales:
Children with absent thyroid did worse than those with ectopic/normally situated glands on the McCarthy scales (Murphy 198670)
Intelligence Quotient (IQ):
PIQ higher in ectopic thyroid patients, V IQ higher in the agenesis patients. A more homogenous development of intellectual ability for children with
ectopic thyroids (Battisti 199658)
Poorer VIQ, PIQ and FSIQ for thyroid agenesis patients, relative to dyshormonogenetic or ectopic patients (Salerno 199946)
Absent thyroid predictive of poorer PIQ at 6yrs (Heyerdahl 199160)
Absent thyroid associated with worse WISC-III (IQ) scores (Song 200168)
Absent thyroid associated with poorer IQ scores (Dimitropoulos 200932)
Wider cognitive skills:
Children with absent thyroid glands performed worse than those with dyshormonogenetic and ectopic glands on various developmental scales
(Rovet 199262)
Outcome based on school reports were marginally more favourable for ectopic patients (Connelly 200135)
Absent thyroid associated with poorer intellectual performance at age 5 (Rovet 199969)
Behaviour:
Inhibition control was better for children with absent thyroid glands (Alvarez 201057)
Bone age Preschool ability scales:
Predicts performance on the McCarthy scales at 3yrs (Murphy 198670)
Predicts development at 2 and 6yrs (Heyerdahl 199160)
Intelligence Quotient (IQ):
Associated with WISC-R scores at 8yrs (Connelly 200135)
VIQ significantly higher in patients with bone age >32 weeks (Campos 199536)
Predicts PIQ at 13yrs, and visuo-spatial ability (Rovet 199969)
Wider cognitive skills:
Correlated with 6th grade phonological processing skill, reading & grammatical sensitivity (Rovet 200065)
On various developmental indices, patients with intrauterine CH were significantly outperformed by patients with postnatal CH (Rovet 199262)
Correlated with increased risk of late entry into 6th grade (Leger 200161)
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8.2.4 Withdrawal of treatment to assess transience or permanence of CHT
Four studies examined the proportion of CHT diagnoses which were later found to be transient; all
described withdrawal of treatment at three years of age and assessment of serum hormone levels
without treatment as the method for assessing transience (Table 12).
Table 12: Studies describing withdrawal of treatment at 3 years of age
Hulse 198254: One out of 32 (3%) patients remained euthyroid after treatment withdrawal.
Costa 199859: 11 (4 preterm) of 23 cases remained euthyroid after withdrawal. Replacement
thyroxine dose was lower in those found to have transient CHT, and TSH normalised more quickly
after commencing treatment.
Corbetta 200920: Permanent CHT was confirmed in 34% of 59 cases.
Hopfner 200511: 39/150 (26%) CHT cases were euthyroid after withdrawal. Screening TSH values
were lower in these transient cases.
Corbetta20 described the results of a treatment withdrawal at three years of age for 59 CHT
children with a thyroid gland visible on scan. After one month of therapy withdrawal, 34% of
children were diagnosed as having permanent CHT. Interestingly, transient CHT was not found
more frequently in children identified through the newborn screening programme using a TSH
>10mU/l cut-off versus a programme using a TSH >20mU/l cut-off.
Other studies, with lower quality ratings, reported widely varying proportions of transient CHT
cases after withdrawal. Hulse54 found that only one patient out of 32 had normal thyroid function
after withdrawal, while Costa59 found that almost 50% of CHT cases were transient.
8.3 Interpretation of the published evidence
Evidence from the literature review suggested that diagnostic investigation after a presumed
positive screening result focused on three tests: serum T4 and TSH levels, thyroid scan and bone
age assessment. Serum T4 and TSH levels were primarily undertaken to confirm newborn
bloodspot findings and rapidly establish the diagnosis. They might also provide information about
the severity of CHT and thus guide initial treatment. Thyroid scans investigated the aetiology of
CHT through defining the absence/presence and location of functioning thyroid tissue. This might
also provide an indication of the severity of thyroid hormone deficiency and guide initial treatment
if undertaken at the time of diagnosis. Finally, bone age assessment at the time of diagnosis could
provide a further guide to severity and requirement for replacement therapy, although it
appeared a less essential test for confirming diagnosis. Diagnostic tests were usually performed
between 10 and 23 days of age, and rarely within the first week or after the first month of life.
Nevertheless, one study provided evidence of a delay in diagnosis of 11-12 days for children who
had initial borderline screening tests results and required repeat screening, compared with
children whose initial screening result was clearly positive.
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Diagnostic test results which indicated the severity of CHT guided the initial dose of replacement
therapy in some studies. Research into late outcomes explored development, cognitive and
psychosocial parameters at two to 16 years of age and findings from these studies strongly
suggested that children with ‘severe’ CHT, defined by absence of a thyroid, markedly low T4 levels
or delayed bone age, had lower IQ, poorer developmental scores and worse school performance
than children without or less severely affected by CHT.
Transience of CHT was only formally assessed in four studies which described the effect of
withdrawal of therapy at three years of age. The proportion of children with transient CHT in these
studies varied very widely from 3% to 50%, making the findings difficult to generalise to other
populations, but this may be due to differences in the severity of CHT affecting participants in
different studies.
Members of the diagnostic test subgroup considered additional relevant published and
unpublished evidence, audit and expert advice as described below.
8.4 Additional evidence relating to different diagnostic tests
Clinical examination
The original standard 16 (2005) recommended a clinical history and clinical examination for every
infant referred for diagnostic investigation. The EWG noted specifically evidence that CHT is
associated with other congenital anomalies in around 5% of affected infants73-76, including
congenital heart defects, hip instability in 3-5% of infants with CHT74 and sensorineural hearing
loss.77 78 Additional expert evidence regarding hearing testing for children with CHT who have had
a negative result on newborn hearing screening was sought from Dr Tony Sirimanna who
presented data from an audit of CHT patients at GOS between 2006 and 2008. Three cases of 85
assessed were found to have sensorineural hearing loss (SNHL), which appears higher than in the
general population and raised the concern that not all might be detected through newborn
hearing screening.
 EWG members considered it important to emphasise that all children referred for diagnostic
testing after a presumed positive screening test for CHT should be carefully examined. In
particular, clinicians should look to exclude associated anomalies, such as heart defects, hip
dislocation and hearing loss.
 Whilst the EWG did not feel that there was sufficient evidence to support referral for
audiological assessment in every child, parental concerns about hearing or speech should lead
to further investigations even if newborn hearing screening was presumed normal.
 EWG members considered that investigation after a presumed positive screening test for CHT
should be undertaken early so that parents can be advised on recurrence risk in future children.
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Family history
The EWG considered evidence relating to collecting information about maternal health, anti-
thyroid medications and iodine status, as well as family history.28 Four recent reports have
highlighted insufficiencies in the dietary intake of iodine in up to 60% of UK girls and pregnant
women79-82, although it is not yet clear if this is having an impact on neonatal screening results.
Further evidence has suggested that maternal veganism during pregnancy might also lead to
transient neonatal hypothyroidism in some newborn infants.83
 EWG members did not consider that there was sufficient evidence to suggest testing for iodine
status in all mothers of children referred for diagnostic investigation, however they concluded
that the clinical history and examination should include enquiry about maternal iodine status
and factors that might affect this.
Serum T4 and TSH levels for diagnosis of CHT
The EWG reviewed additional published evidence supporting the use of laboratory reference
ranges for serum free T4 and TSH in neonates that were appropriate for age and the type of
equipment used.84 85 They were provided by Dr C Evans with unpublished audit data from the All
Wales Laboratory Survey, which highlighted the variation in test methods and reference ranges
used across 11 different Welsh laboratories. Age-related reference ranges were derived from
different manufacturers, historical data or in-house standards.
 EWG members determined that there was an important requirement for robust age- and
method-dependent reference ranges to be developed for free T4 and TSH.
Expert advice relating to thyroid imaging
Details were provided of the different imaging available for diagnostic investigation in infants with
presumed CHT. Radio-isotope scans can identify ectopic thyroids or thyroid agenesis28 86-88 and
may be supplement by an ultrasound scan.89 Ultrasound and radio-isotope scans were compared:
Table 13: Comparison of different types of thyroid scan
Ultrasound Radio-isotopeTechnetium 99m
Radio-isotope
Iodine 123
Availability Readily available Readily available Less available
Radioactivity
absorption
None 6 hour half-life
Low absorbed radiation dose
13 hour half-life
Taken up into hormone
Timing Any time Before or within 5 days of
initiating treatment
Before or within 5 days of
initiating treatment
Results Position of thyroid Position of thyroid
Thyroid tissue activity
Position of thyroid
Thyroid tissue activity
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It was also noted that ultrasound scans may be more accessible in some hospitals and need not be
done within 5 days of initiating treatment as with a radio-isotope scan. However thyroid
ultrasound in neonates requires specialist skills, training and experience and may give misleading
results90, for example an ultrasound scan might identify tissue in the correct location but this
might be non-functioning thyroid. Expert recommendation was that ultrasound scans should not
be routinely done in isolation and must be interpreted with caution.
The EWG were advised that a radio-isotope scan was preferable as it
• provides diagnostic information
• allows the family to be given an explanation of the cause of the CHT
• identifies babies with possible dyshormonogenesis.
An ultrasound scan may also supplement a radio-isotope scan, particularly in infants with apparent
thyroid agenesis on the radio-isotope scan, as this will identify infants with ‘trapping defects, i.e.
thyroid tissue that is present but not functioning normally.
Additional evidence relating to testing maternal thyroid status
EWG members also considered published evidence relating to the potential for maternal thyroid
status91-100 to lead to transient abnormalities in thyroid hormones in neonates, and in particular to
the effect of anti-TSH receptor antibodies (TRAb). Pregnant women might have a history of
previous thyroid dysfunction, thus taking a maternal history to explore thyroid problems is
important. However testing of the mother may also be required in other cases as mother’s may
not manifest symptoms and signs of hypothyroidism, yet still have abnormal thyroid function that
interferes with their baby’s screening test results.
 EWG members agreed that further research was required in this area.
Additional evidence relating to thyroglobulin tests
Thyroglobulin (Tg) is a sensitive biochemical marker for the presence of thyroid tissue and may
also provide additional information about aetiology and underlying genetic mutations.101
Production of Tg is regulated by TSH so testing for Tg must be undertaken within five days of
commencing replacement therapy (as for radio-isotope scans). Tg levels may also be affected by
anti-thyroglobulin antibodies so antibody testing should be performed. Published evidence
relating to the measurement of thyroglobulin as a diagnostic test was considered.85 101 102 103
Authors of two papers suggested that thyroglobulin could complement ultrasound scanning and
avoid the need for radio-isotope scans.
 EWG members considered that there was no evidence to suggest that thyroglobulin should be
removed from the list of desirable tests but emphasised that Tg measurement should be
undertaken prior to or within 5 days of initiating treatment and should be accompanied by
testing for Tg antibodies.
Final Report (January 2013) 52 | Page
Confirmation that CHT is permanent: withdrawal of therapy
Clinical guidelines and published evidence were considered by the EWG with regard to defining
the cause of CHT and the establishment of an early CHT diagnosis as permanent.28 40 70 73 104-106 It
was proposed that CHT should be considered permanent if:
 Thyroid scan reveals an ectopic or absent thyroid gland
 Serum TSH>10mU/L after the first year of life (presumably because of insufficient T4
replacement).
If a permanent cause of CHT has not been established, then further tests should be undertaken to
confirm this at a later date. Testing for permanence through a ‘withdrawal of therapy’ testing
would usually be performed after the child is 3 years of age and would typically involve:
 Discontinuation of levothyroxine (LT4) for 30 days
 Measurement of free T4 and TSH.
As severely affected children may become clinically hypothyroid by 30 days, reducing the dose by
half might be considered as an alternative. If after 30 days, the TSH is >20mU/L, then CHT is
confirmed to be permanent and therapy should be resumed. If the serum TSH has not increased,
then therapy should be discontinued for a further 30 days and serum free T4 and TSH testing
repeated.
 EWG members noted that if therapy was withdrawn for such testing, great care must be taken
that the child is not lost to follow-up and that therapy is re-started if there is any suspicion of
hypothyroid symptoms. If such testing is inconclusive, it may be repeated at a later date but
the child should remain on therapy in the meantime.
 EWG agreed that a new standard should make recommendations for confirming the
permanence of CHT in all children. A Diagnostic Protocol was drawn up to define the steps in
the diagnostic testing pathway leading to definition of a CHT diagnosis as permanent.
8.5 EWG Final Recommendations and Revised Standards relating to
Diagnostic Investigation
Clinical evaluation and confirmatory diagnostic tests
The clinical history and examination of the baby, mother and wider family was addressed in the
former 2005 Standards 16 (2005). Members considered this should now become Standard 13 with
additional notes for clarification.
New Standard 13. The clinician responsible for assessing the baby with a positive screening result
shall take a clinical history and perform a clinical exam.
(See Note 1)
Note 1: Babies with CHT are more likely to have associated anomalies, particularly congenital heart
defects and mild hearing loss and require careful neonatal examination. A complete history,
including maternal thyroid status (previous history of thyroid dysfunction, maternal anti-thyroid
medications), maternal diet (e.g. vegan or other low iodine diet) and family history should be
obtained.
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 EWG members did not consider that there was sufficient evidence to support audiological
referral in all children, however they highlighted that a hearing test should be considered if
there were concerns about hearing or language development even if the newborn hearing
screening test result appeared normal.
Standards 17 and 18 (2005) became new Standard 14 with an accompanying note regarding the
need to use appropriate reference ranges.
New Standard 14. Diagnostic tests considered essential in the baby are:
a) Free T4 (plasma or serum)
b) TSH (plasma or serum)
(See Note 2)
Note 2: Diagnosis using free T4 and TSH should be performed on a plasma or serum sample using
the appropriate age-related reference range as defined by the laboratory in relation to the
equipment used.
 EWG members considered that the previous Standards 19-20 (2005) concerning tests in the
baby should remain as ‘Desirable additional diagnostic tests’.
Desirable additional diagnostic tests
New Standard 15. Appropriate imaging techniques (radio-isotope and/or ultrasound scans), may
help to establish whether the thyroid gland is
a) normally situated and normal in size and shape
b) normally situated but abnormal in size and shape
c) ectopic
d) absent.
(See Note 3)
Note 3: A radioisotope scan and an ultrasound examination may establish the cause of the child’s
CHT and indicate whether the condition is likely to be permanent. Initiation of treatment should
not be delayed whilst waiting for an isotope scan, which can be performed up to 5 days after
starting therapy. An ultrasound scan can be performed at any stage and investigation need not be
confined to the neonatal period. These investigations may increase awareness of potentially
related problems such as deafness and can provide information about recurrence risk. Recurrence
is unusual in the case of thyroid dysgenesis but there is likely to be autosomal recessive
inheritance with a 1:4 recurrence risk for families of babies with thyroid dyshormonogenesis. Both
isotope scanning and thyroid ultrasound in neonates require specialist skills and can generate
misleading results.
 EWG members considered that the thyroid imaging at the time of diagnosis was desirable to
confirm aetiology and, if absence of the thyroid was confirmed, this might avoid the need for a
future ‘withdrawal of therapy’ or ‘trial off-therapy’ to test for transient CHT.
Final Report (January 2013) 54 | Page
New Standard 16. In addition, the following test may be helpful:
a) Thyroglobulin
(See Note 4)
Note 4: Plasma thyroglobulin ideally needs to be measured on a sample taken prior to the start of
treatment; this must not delay initiation of treatment. If plasma thyroglobulin is detectable then
there must be some thyroid tissue present. Concentrations will be undetectable in thyroid
agenesis.
 EWG members considered that it was important to clarify aspects of the methods and
interpretation of the thyroglobulin test in the notes.
Advisable tests in the mother
The EWG recommended rewording Standard 21 (2005) as below:
New Standard 17. Diagnostic tests considered advisable in the mother to exclude interference in
the infant’s TSH measurement and to exclude thyroid dysfunction in the mother include:
a) Free T4 (plasma or serum)
b) TSH (plasma or serum)
These investigations should be extended to include an assessment of TSH antibody receptor status
in mothers with a current or previous history of autoimmune thyroid disease.
 The EWG considered it important to highlight the importance of always considering
investigations in the mother by creating a new subheading ‘Advisable tests in the mother’.
Assessment of Permanence of Hypothyroidism
A new Standard 22 was proposed:
New Standard 22. In cases where the cause or persistence/permanence of hypothyroidism has
not been confirmed (see Diagnostic Protocol), confirmatory testing should be undertaken at 2-3
years of age, with thyroid function tests checked 4-6 weeks later.
 The EWG determined that a clear protocol for diagnostic confirmation of CHT, up to the point
of clarifying if withdrawal of therapy was required to define whether CHT was transient or
permanent, should be specified as part of the new standards.3
3 After the public consultation on the revised standards, New Standard 22 was amended to include a
recommendation for regional and national audit of outcomes: ‘The outcome should be fed back to the
regional endocrine centre to facilitate regional and national audit.’ This amendment has been included in
the final list of revised standards in the Executive Summary of this report.
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8.6 Recommendations for further research
The EWG recommended that further research would be merited to define age- and method-
related reference ranges for serum levels of free T4 and TSH, as well as to investigate TSH
interference in thyroid-receptor antibody assays.
9 Referral Pathway and Clinical Responsibilities
9.1 Original (2005) ICR standards relevant to the referral pathway
Children who have a positive screening result are referred for diagnostic testing and further care.
A subgroup considered evidence relating to the referral pathway and clinical responsibilities for
further care as described in standards 11-15 and 25 from 2005 (Box 7).
EWG members drew on the following sources:
• Specifically designed questionnaire to newborn screening laboratories
• British Society for Paediatric Endocrinology & Diabetes (BSPED) Clinical Standards 2010
• UK Newborn Screening Programme Centre information leaflets
• Expert clinical opinion.
Box 7: Standards 11-15, 25 (2005)
11. Babies with positive screening results for CHT should be referred to a designated clinician as
defined by the BSPED who has access to the full range of diagnostic investigations
recommended.
12. Parents should be offered an appointment with a designated clinician within at least 3 days
of being informed about their baby’s positive screening result.
13. Laboratories should notify a positive screening result verbally (by telephone) as well as in
writing (by fax/email) to a designated clinician and either the GP and health visitor, or the
health professional responsible for communicating results. This initiates the clinical referral
as measured within standard 6 of the process standards.
14. The GP, health visitor, midwife or other health professional responsible for making initial
contact with the family to explain the positive screening result should be provided with:
a. Standardised information – for parents and health professionals
b. The contact numbers of the designated clinician, local health professionals as
appropriate and details of parent support groups
c. Details of the time and date of an appointment with the designated clinician.
15. Parents should be offered an appointment with the designated clinician on the next
working day of hearing about a positive screening result. They therefore should not
normally be notified of a positive screening result of Fridays, Saturdays, or Sundays
preceding Bank Holidays.
25. Once treatment has been started, a baby should be reviewed, with a blood test at each
visit. The timing of such visits may vary according to local circumstances but it is suggested
should occur at 2 weeks, 6 weeks, 3 months, 6 months, 12 months after treatment is
started, and thereafter as indicated, with management complying with BSPED
recommendations for interpretation of tests and dosage. Visits may occur more frequently
as necessary.
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9.2 Results from the laboratory survey
All 16 newborn screening laboratories responded to a questionnaire based on the above
standards.
Laboratory staff members were asked to describe what systems for referral work well and which
do not work, what they would change, who they consider should manage local CHT referrals,
whether any local areas lack a designated paediatrician for CHT and what happened when the
designated paediatrician or deputy was not available to take a referral.
Laboratory staff responses to who should manage CHT cases in their region were:
 Paediatrician (n=6)
 Paediatric endocrinologist (n=3)
 Paediatrician with an interest in CHT/endocrinology (n=2)
 Paediatrician and clinical nurse specialist (n=1)
 Other/no view (n=4)
However, laboratory staff also suggested that care immediately after referral might differ from
long-term follow-up care, for example that immediate diagnosis and early management should be
concentrated in specialist centres but long-term care provided in local centres. There was an
emphasis on the need for consistency in early management. Drawbacks to locally provided care
were highlighted as the lack of a specialist or named responsible consultant leading to variation in
care provision. No formal shared care protocols were identified and few examples of shared care
were elicited and some centres are moving towards tertiary centre follow-up long-term.
Nevertheless, laboratory staff stated that a designated clinician to receive all referrals and six
monthly multidisciplinary meetings worked well to improve consistency and quality of treatment.
Difficulties were highlighted in the use of the term ‘designated clinician’ as few areas are able to
refer to a specialist during periods of out-of-hours care.
Laboratories stated that they used a wide variety of routes for referring or communicating
presumed positive screening results to a responsible clinician, however all initiated this with a
telephone call and the majority followed this with a written communication by letter or fax. Some
laboratories preferred to notify GPs also.
Of the 16 laboratories surveyed, three provided the UKNSPC leaflet with the referral, one was
aware that the clinician already has the leaflet, one was unsure and 11 did not provide the leaflet.
In some areas a locally developed leaflet was provided.
 EWG proposed that ‘designated clinician’ might be more appropriately described as a
‘named paediatrician with a designated deputy’ as they key issue was for the initial referral
and on-going care to be provided by a paediatrician who was trained and experienced in
CHT and had a sufficiently high volume of referrals per annum to maintain this expertise.
 EWG members proposed that a statement highlighting the need for specialist support
networks be included in the standards.
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 EWG members considered that standards 12 and 15 were contradictory regarding the
timing of referral and proposed that these be combined into a single standard.
9.3 BSPED Clinical Standards 2010
No clinical training standards or requirements currently exist to define ‘expertise’ in managing
CHT. CHT is defined as a Level 2 endocrine disorder, i.e. a ‘relatively common endocrine disorder’.
These are defined by BSPED as “conditions with a need for input from a paediatrician with an
interest in endocrinology usually managed at local … clinics with occasional input by a paediatric
endocrinologist on a shared care basis with local teams.”
 EWG members proposed that a statement highlighting the need for specialist support
networks be included in the standards.
9.4 UKNSPC leaflets
The UKNSPC produces a leaflet aimed at parents and developed with parents, to communicate
information about CHT screening and about a suspected diagnosis of CHT. This leaflet is intended
for clinicians to share with parents when a child is referred for further investigation. However the
UKNSPC reported that many clinicians are unaware of the leaflet and produce a local leaflet or use
information downloaded from the BSPED website, ‘Nick’s Notes’ and the Child Growth Foundation
some of which require updating.
 EWG members agreed that the UKNSPC leaflet required updating and wider dissemination.
This might be supported by including distribution of the leaflet within the new standards.
9.5 EWG Final Recommendations and Revised Standards relating to
Referral Pathways and Clinical Responsibility
Referral of babies with positive screening results
Standards 11, 12 and 15 (2005) were revised by the EWG and became new Standards 8 and 9.
These defined the need for a designated named paediatrician and deputy, support from a regional
specialist clinical network and provision of a timely appointment to parents.
New Standard 8. The laboratory shall refer babies with positive screening results for CHT the same
or next working day.
Referral is to a paediatric endocrine team (regional specialist team) or to a clearly identified lead
paediatrician with a special interest in CHT or experience of managing these patients.
Appropriate failsafe mechanisms must be in place to ensure CHT suspected babies have entered
into the diagnostic pathway.
Clinicians should work to a common protocol and have access to the full range of diagnostic
investigations recommended.
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Where referral is out-with a regional endocrine centre, the regional specialist team should be able
to provide support and facilitate access to diagnostic investigations where required.
New Standard 9. The first clinical appointment with the paediatrician must take place on the same
day or the next day after parents are informed of their baby’s positive screening result.
Communication flows
Standards 13 and 14 (2005) were extended by the EWG and became new Standards 10-12. These
standards clarified the methods for communicating results between the laboratory and clinicians,
and between clinicians and parents, and also the information to be provided.
New Standard 10. Laboratories shall notify a positive screening test (blood spot results expressed
as a whole number), verbally and in writing by secure fax or email, to the lead paediatrician or
deputy and the health professional responsible for communicating results.
This notification should include a link to the standardised diagnostic and initial treatment protocol.
This initiates the clinical referral of screen positive cases.
New Standard 11. The result should be communicated by an informed health professional.
The health professional making initial contact should provide the following information to the
family:
a. UKNSPC standardised parent information ‘When CHT is suspected’ (via hard copy
or web link).
b. Details of the time and date of the appointment with the paediatrician and
appropriate contact telephone numbers.
New Standard 12. The laboratory should provide a link to a standardised diagnostic and initial
treatment protocol.4
4 Following responses to the public consultation and identification of the need for national outcomes audit,
New Standard 12 was amended to: ‘The outcome of the first appointment should be reported to the
newborn screening laboratory. The regional endocrine centre should also be informed about diagnostic
outcome to facilitate regional and national audit.’
Final Report (January 2013) 59 | Page
10 Initiation of treatment and clinical follow-up
10.1 Original (2005) ICR standards relevant to treatment and follow-up
Children with CHT should be commenced on treatment as soon as possible as laid out in standards
22-24 in 2005 (Box 8). Standard 25 (Box 8) defines follow-up and has also been addressed under
the previous sections relating to diagnostic investigations and clinical responsibilities.
EWG members drew on the following sources:
• Evidence from the literature review
• UKNSPC data relating to the timeliness of treatment.
Box 8: Standards 22-25 (2005)
22. A baby in whom the essential confirmatory diagnostic tests are positive on the initial
screening sample should commence treatment by:
Developmental standard: 18 days of age (100% of infants)
Core standard: 21 days of age (100% of infants)
23. Starting dose of levothyroxine sodium should be 10 microg per kilogram per day.
24. Suspensions should not be used as the dosage may be unreliable. Parents should be given
verbal and written information about how to give tablets to their baby.
25. Once treatment has been started, a baby should be reviewed, with a blood test at each
visit. The timing of such visits may vary according to local circumstances but it is suggested
should occur at 2 weeks, 6 weeks, 3 months, 6 months, 12 months after treatment is
started, and thereafter as indicated, with management complying with BSPED
recommendations for interpretation of tests and dosage. Visits may occur more frequently
as necessary.
10.2 Results from the evidence review: initiation of therapy
A total of 82 papers discussed initial treatment variables, of these only one received a high quality
rating, while 42 received a medium plus (M+) quality rating, 26 a medium minus (M-) quality
rating, another 14 a low rating. The focus of this discussion will be on the M+ rated papers. Of the
M+ papers, 18 discussed treatment variables in relation to outcome.
Age at commencement of therapy
The mean age at commencement of thyroxine replacement therapy ranged from seven to 33 days
of age (Table 13). In most studies, replacement therapy was commenced within the first month of
life, however Mathai29 noted that a borderline screening result was associated with a mean delay
in therapy of approximately 11 days. Kooistra72 reported earlier commencement of therapy for
children with more severe CHT, defined as a lower serum T4 or absence of the thyroid at initial
diagnosis, however also found no improvement in outcomes from advancing the start of
replacement therapy from 28 to 20 days of age.
A few studies described the timing of treatment onset and later outcomes, usually in respect of
intellectual outcome. For example, Rovet found that poorer performance IQ scores, visuol-motor
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ability and poorer language ability were associated with a later onset of treatment.62 69 Salerno
and colleagues45 found a correlation between higher full scale IQ scores and earlier age at start of
treatment. Finally, Battisti58 found that a group of children with delayed onset of therapy
demonstrated poorer performance on various measures of mental capacity, such as the WISC-R
test for IQ, the Bender test, and Toulouse-Pieron test of attention. Importantly, Rovet107 noted
that children who commenced replacement therapy within the first two weeks of life were less
likely to be hearing impaired than those who commenced treatment later. She suggested that
there might be a critical period within the first two weeks of life, during which thyroxine is crucial
for normal development of hearing. Heyerdahl71 found that children with delayed growth in
childhood had started treatment at an older age than those with normal growth.
Table 13: Age at which treatment was commenced in different studies
Age at initiation of treatment References
1st week of life (0-7 days of age): Mathai29 (Day [D.] 2-3 if positive screen)
Arenz108 (D. 7)
2nd week (8-14 days): Alvarez57 (D. 8)
Hopfner11/Dimitropoulos32/Gruters21 (D. 9)
Jones17/Selva109 110 (D. 11)
Rovet69 107 (D. 12-33)
Gjurkova8/Connelly35 (D. 13)
Bongers-Schokking111 112/Winkler67/Simoneau-Roy113 (D. 13-14)
Dubuis31/Brown114 (D. 14)
Mathai29 (D. 14 if borderline screen result)
3rd week (15-21 days): Rovet69 107 (D. 12-33)
Ilicki115 (D. 15)
Law13 (D.17)
Glorieux33 (D. 18)
Toublanc43 (D. 18-21)
Heyerdahl53 (D. 19)
Kempers72 (d. 20)
Pharaoh12 (D. 21)
4th week (22-28 days): Niu50 (D. 22-23)
Fuggle (D. 23)
Kooistra116 117 (D. 23-24 if agenesis)
Oerbeck41 42/New England Collaborative118/Adachi119 (D. 24)
Moreno120/Weber121 (D. 25)
Salerno45 47 48 (D. 25-28)
Murphy70 (D. 27)
Bargagna122 (D. 28-30)
Delvecchio51 (D. 28)
Within the first month: Illig123
Germuk124
After the first month or 28 days: Hulse54 (D. 31)
Moschino56 (D. 33)
van der Sluijs125 (D. 28-39)
Nakazimo9 (D. 31)
Battisti 58(D. 33)
Kooistra116 117 (D. 52 if dysgenesis)
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Initial dose of thyroxine replacement therapy
There were 64 papers that reported dose at initiation of treatment (Tables in Appendix 3). In
addition, Hrytsiuk presented a systematic review of dose at initiation of therapy. Marked variation
in initial dose levels existed across papers. The lowest reported dose was around 2µg/kg/day38 and
the highest 15 µg/kg/day. Doses varied within a study either to adjust for severity, by time period
or because of a randomised control trial design. The majority of studies reported doses in
micrograms per kg per day (µg/kg/day), however some only reported the total amount per day
(i.e. µg/day) and occasionally other units were employed.
All except two studies40 126 reported a positive relationship between dose level and intellectual
outcome.45 53 61 117 127 Rovet and Ehrlich127 found that at seven years of age, CHT patients receiving
a high initial dose of levothyroxine (>7.8 µg/kg) had a higher full scale IQ and verbal IQ compared
with those patients receiving a low initial dose (<7.8 µg/kg). Children started on a dose >7.8 µg/kg
had significantly higher scores on the verbal comprehension, similarities and arithmetic subtests of
the WISC-R and, at age 8 years, scored higher on the McCarthy memory subtests and the Passage
comprehension subtest of the Woodcock Reading Mastery scale. Finally, Leger and colleagues61
reported that a dose of less than 7µg/kg/day was associated with an almost twofold increase in
the risk of late entry into the first grade of secondary school.
Salerno45 reported findings from a study where participants were split into three dosage groups:
Group 1: 6.3 µg/kg/day; Group 2: 9.1 µg/kg/day; Group 3: 13.4 µg/kg/day. At four years of age,
the full scale IQ of patients in group 3 was significantly higher relative to patients in Groups 1 and
2 and a significantly lower performance IQ was observed in patients from Group 1 compared to
both Group 2 and 3 patients. The subtests most affected were comprehension, mazes, geometric
design and block design.
The impact of initial dose of thyroxine on outcomes varied by study: Kooistra128 reported that
initial dose accounted for 21% of the variance in verbal IQ at age 20, whilst Heyerdahl53 found that
it only accounted for 12% of the variance in mental development scores of the Bayley’s Scales of
Infant Development. The reason for this discrepancy is unclear, but differences in test measures
and times of testing between these studies may have influenced the results.
There was less consensus about the relationship between initial dosage and attention and
behavioural outcomes. Rovet & Hepworth129 reported better attention scores for patients who
had a lower initial dose of thyroxine replacement. In an earlier study, Rovet noted a higher
incidence of internalising behaviour problems (social withdrawal, anxiety/depression, social
problems, delinquency and aggression subscales of the Child Behaviour Checklist; conduct and
hyperactivity problems on the Conners Scales) for children commenced on high dose replacement
therapy.127 Of three children with behaviour problems in the psychopathic range, all had a starting
dose > 18 µg/kg. In contrast, Oerbeck42 found that children started on a higher initial dose of
thyroxine achieved better scores on the Freedom from Distractibility test.
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In terms of growth variables, only one study discussed this in relation to initial dose level.
Salerno’s study45 evaluated bone maturation under three treatment regimes, described above,
and reported delayed maturation in Group 1 children receiving the lowest does of replacement
therapy relative to Groups 2 and 3 for the first two years of life. However, bone maturation for this
group of children ‘caught up’ by the third year of study suggesting only temporary impairment.
Initial dose and normalisation of hormone levels
Most studies found that a higher initial dose led to more rapid normalisation of both T4 and TSH
levels. However, some studies reported a period of ‘overtreatment’, usually demonstrated by
abnormally high serum T4 levels, with high initial doses. Selva110, in a randomised controlled trial,
assessed hormone levels up to 12 weeks after treatment onset in infants receiving one of three
treatment regimes: Group1: 37.5 µg/d; Group 2: 62.5 µg/d for three days then followed by 37.5
µg/d; Group 3: 50 µg/d). She found that children in Groups 2 and 3 normalised serum T4 by day
three of treatment whereas children within Group 1 took one week to achieve normal T4 levels.
TSH levels were normal by week 2 for Group 3, receiving the highest dose, while infants in Group 1
only achieved normal TSH levels by week 12. Interestingly the group commencing on a high dose
then dropping to a lower does never achieved TSH values in the normal range during the follow-up
period. All groups showed periods of overtreatment, when T4 values were above the normal
range; for Groups 1 and 2, this was between weeks 2 and 4, whereas the highest dose group
experienced overtreatment from week 3 to 12. Similar findings have been reported by other
studies.29 38 45 130 Nevertheless, in Rovet & Ehrlich’s study127, children who commenced on a lower
starting dose had higher T4 levels at 7 and 8 years of age, and higher TSH levels at 7 years,
suggesting that they had been given higher therapeutic doses subsequent to their initial therapy
with the aim of ‘correcting’ serum T4 and TSH levels.
In conclusion, the optimal starting dose of thyroxine remains to be established. Most studies
appear to suggest that a dose of ≥10 µg/kg/day is needed to achieve normalisation of thyroid 
hormones quickly, and that this dose is associated with improved long-term outcomes. However,
some studies also suggest that using high doses of thyroxine to rapidly normalise T4 levels might
result in periods of overtreatment.
Timing of Treatment and Initial Dose
One study analysed outcomes in relation to a combined time of treatment/initial dose variable
and children were divided into early/high, early/low, late/high and late/low groups depending on
when they started treatment and their initial dose. Bongers-Schokking’s group131 analysed mental
development and psychomotor development scores of infants with severe and moderate CHT
(based on initial T4 levels). They found that for children with severe CHT, only those treated early
and with high dose therapy had mental development scores comparable with those of patients
with mild CHT and a reference control population. Within the mild CHT group, children treated
early with low or high doses, and those treated late but with high doses had mental and
psychomotor development scores comparable with the reference control population. Children
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with mild CHT who commenced treatment late and at low doses had lower scores. Moreover, the
early treatment/high dose group achieved normal serum T4 concentrations by day 16, while those
of the other three groups were only normal by day 24. As this is the only study to discuss this
combined variable in relation to outcomes, no firm conclusions can be drawn.
Formulation of levothyroxine
Two studies described the formulation of treatment; Jones130 and Selva110 both described the
administration of crushed tablets as the preferred formulation although liquid suspensions were
used by up to one third of clinicians.
Summary
Findings from most studies supported an effect of initial dose of therapy on later outcomes, with
worse intellectual outcome associated with lower initiating doses. However, it is unclear whether
this relationship is linear or if there is a cut-off dose above which intellectual outcomes should be
optimal. Few studies attempted to relate current levels of treatment to the initiating dose and to
outcomes. Higher initiating doses of replacement therapy were associated with better outcomes
in terms of development and cognitive abilities, however, Rovet noted that high initiating doses
were associated with increased attention and behaviour problems, in particular where doses were
>18 µg/kg/day. Whilst high initial doses led to more rapid normalisation of serum hormone levels,
they were also associated with periods of over-treatment.
Several studies suggested that earlier onset of treatment was associated with improved cognitive
and developmental outcomes. In particular, Rovet found that children who commenced treatment
within the first two weeks of life were less likely to be hearing impaired, and proposed that a
critical period for commencing treatment may exist.
Based on the evidence presented here, the relationship between outcomes of CHT and the age
and dose at initiation of replacement therapy is complex, and may be influenced by the severity of
the underlying CHT and/or hypothyroidism during prenatal development. Worse outcomes may
be observed both with low and very high initiating doses; the influence of subsequent changes in
therapy during follow-up has not been fully explored. Nevertheless, early initiation of therapy is of
benefit and initiation of therapy within the first two weeks of life may avert hearing impairment
associated with CHT.
10.3 Evidence from the literature review relating to follow-up
There were 28 papers which discussed frequency, purpose and place of clinical follow-up after
initiation of replacement therapy. Twenty-three were of moderate quality (18 M+, 5 M-) and a
further five were of low quality. Clinical follow-up regimes described in these papers are
summarised in Table 14 below. The timing of the first follow-up appointment was often not
specified, and clinical practice regarding frequency of monitoring varied widely in the first few
months after commencing therapy. Where information about the managing clinician was
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provided, this was most often a paediatrician or paediatric endocrinologist who supervised
therapy in the first few years of therapy. The aim of follow-up within most studies was focused on
monitoring and adjusting the dose of levothyroxine in response to achieve optimal levels of serum
T4 and TSH.
No studies appraising follow-up and monitoring from the perspectives of children or families, or
evaluating outcomes using different methods of follow-up, were identified. Thus, while the
heterogeneity of different monitoring and follow-up regimes can be presented here, the relative
effectiveness of these cannot be assessed from current evidence.
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Table 14: Studies reporting clinical follow-up
Reference 1st follow-up Frequency Who Tests Purpose oftests Influence
Delvecchio et
al (2007)51
Not stated Every month in first
trimester, then every
three months till 3 years
of age, then every 6
months.
Not stated Physical and
audiological exam;
hormone assay,
length/ height (H)
performed monthly
Measure height,
and monitor
thyroid hormone
value (maintain
in normal range)
LT4 dose adjusted to
keep TSH within
normal limits, and T4
in the upper half of
the normal range
Mathai et al
(2008)29
Not stated Weekly for 4 weeks, then
at 6 weeks, then monthly
until 24 months of age
and then 3 monthly.
Paediatric
endocrinologists
Thyroid hormone test Monitor
hormonal levels
Maintain T4 in the
upper half of the
normal range.
Alvarez
(2010)57
Not stated Every month during the
first 6 months after
initiating treatment
Not stated TSH and T4 Monitor
hormonal level
Not stated
Song et al
(2001)68
Not stated 1, 3, 6, 9, 12, 18, 24, and
36 months of age.
Paediatric
endocrinologist
TSH and T4 Monitor
hormonal levels
Not stated
Dimitropoulos
(2009)32
Not stated Initially every 2–4 wk,
then every 3–6 mo,
Paediatrician TSH and T4 Monitor therapy Dose adjustments
Ilicki &
Larsson
(1988)22
Not stated 1, 3, 6, 9, 12 and 18
months of life and on
each birthday thereafter.
Paediatrician Physical examination;
T4, TSH in serum.
Not stated Not stated
Dubuis et al
(1996)31
4 weeks after
therapy onset
3.6.9.12 and 18 months Not stated Plasma TSH, FT4 and
TT4. X-ray12 months
Compliance
bone age.
Not stated
Salerno et al
(1999)46
Not stated At 3, 6, 9 and 12 months
during the first year, then
every 3 or 6 months until
3rd year of age, and
annually thereafter.
Not stated Not stated Dosage adjusted
to keep serum
T4/TSH levels in
normal range.
Not stated
Leger et al
(2001)61
Not stated Two to three times a year
from the age of 6 months
Not stated TSH, FT4 Control TSH and
FT4
Not stated
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Table 14: Studies reporting clinical follow-up (continued)
Reference 1
st follow-
up Frequency Who Tests Purpose of tests Influence
Rovet et al
(1992)62
Not stated Monthly until 4 months,
then at 6, 9, 12 and
18 months; then yearly
Not stated Growth and
thyroid functioning
Maintain thyroid hormone
levels in the upper end of the
normal range
Not stated
Salerno et al
(2002)45
After 4
weeks of
treatment
Every 3 months until age
of 2 years, every 6
months thereafter
Not stated T4, T4 and TSH Keep serum T4 levels in the
upper normal range and serum
TSH within the normal range.
Dose adjustments
Battisti et al
(1996)58
1 month
after starts
therapy
Every 3 months
during the first year of
therapy, and annually
thereafter
Not stated Serum TSH,TT4,
FT4 and T3
Assess adequacy of therapy Not stated
Adachi et al
(2003)119
Not stated 1–3 month intervals, at
least twice a year
Endocrine
specialist
Height, TSH Monitor growth and adequacy
of treatment
Thyroxine doses
adjusted to keep
TSH below
10 mU/L.
Bargagna et al
(2000)132
Not stated 2, 3, 6, 9, and 12 months
in first year then every 3
months up to 3 years
old, then every 6 months
Not stated T4 and TSH Maintain TSH in 0.5-5mU/L
range
Dose adjustment
Bongers-
Schokking et al
(2000)111
1, 2 and 3
weeks after
treatment
onset.
1.0, 1.7, 2.8, 4.0, 5.9, 8.5
and 11.5 months.
Not stated FT4, TSH Not stated Dose adjustments
Jones et al
(2009)130
7-21 days
after start of
treatment
3, 6, 12, 18, 24 and 36
months of age.
Not stated Weight, length, bone
age, thyroid function,
dose
To monitor growth and
adequacy of treatment
Dose adjustments
Germak &
Foley (1990)55
Twice during
first weeks
of treatment
Monthly for the first 6
months of therapy, then
every 3 to 6 months.
Not stated T4, FT4, TSH Maintaining serum T4
in upper normal range; serum
TSH within the normal range
Dose adjustments
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Table 14: Studies reporting clinical follow-up (continued)
Reference 1
st follow-
up Frequency Who Tests Purpose of tests Influence
Campos et al
(1995)36
Not stated 3-6 weeks for 6 months,
then 2-4 month intervals
Not stated T4 and TSH Keep T4 in mid-normal range Dose adjustments
Bargagna et al
(1994)133
Not stated 3, 6, 9, 12, 18 and 24
months
Not stated Not stated Not stated Not stated
Nakamizo et al
(2007)9
Not stated Every 2 months up to 12
months of age then
every 3 months.
Not stated Biochemical and
clinical
Not stated Not stated
Arenz et al
(2008)108
Not stated 2-3 times per year Not stated Not stated Not stated Not stated
Kooistra et al
(1996)117
Not stated Weekly, increasing to
every 3 months during
the first 2 years, then
every 6 months.
Not stated Plasma T4 and TSH Monitor treatment compliance Dose adjustments
Simoneau-Roy
(2004)113
Not stated 1.5, 3, 6, 9 and 12
months, then 6 monthly
until 3 years, then yearly
Not stated Plasma TSH, T4, T3,
x-rays (at 1 & 3 years)
Maintain plasma TSH 0.5 to
5.0mU/L. Bone age.
Dose adjustments
Moschini
(1986)56
1 month
after onset
of therapy
Every 3 months in first
year, then 6 monthly
Not stated Serum T3/T4/ TSH,
physical exam,
length, weight, head
size,
annual x-ray
Monitor thyroid function,
growth, bone maturation
Not stated
NECHC
(1984)134
2 & 6 weeks
after starts
treatment
Not stated Hormone
concentrations
Not stated Not stated
Vogiatzi &
Kirkland
(1997)135
Not stated 2 month intervals during
the first year then 3-
month intervals.
Not stated T4 and TSH Maintain T4 levels in the
normal range
Dose adjustments
Bargagna
(1999)122
Not stated Every 3 months in the
first year of life, then
every 3–6 months.
Not stated FT4, TSH and T3 Maintaining serum TSH in
normal range.
Dose adjustments
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Summary
Across most studies, follow-up within the first year of life was every three months, and this
frequency was often decreased to every six months during the second year of life. A few authors
reported more frequent assessment within the first month of life. Follow-up provided an
opportunity for assessing T4 and TSH levels and for adjustment of replacement therapy dose
regimes on the basis of these and was therefore undertaken by a paediatrician although this
was not always a specialist endocrinologist.
10.4 Additional evidence from the UKNSPC
The UKNSPC defines acceptable and achievable standards for commencing treatment after
positive newborn bloodspot screening results. Standards are set by considering the clinical
urgency and the need to commence therapy in a timely manner to prevent unwanted sequelae.
To determine whether the standards were consistent with current practice, the median and
interquartile ranges (IQR) currently achieved against these standards were estimated by
UKNSPC staff. Currently the median age at commencing therapy for a child with a positive
screen on the first sample is 10 days (IQR 8-13 days) and for a child who has positive screen on
a repeat sample, it is 20 days (IQR 18-25 days).
 EWG members agreed that, for a screening test which was positive on the first sample,
the achievable standard would be 14 days of age and the acceptable standard would be
17 days of age.
 EWG members agreed that, for a screening test which was positive on the repeat
sample, the achievable standard would be 21 days of age and the acceptable standard
would be 24 days of age.
10.5 EWG Final Recommendations and Revised Standards for
Treatment and Follow-up
EWG members agreed that the new standards should be:
New Standard 18. A baby in whom a diagnosis of CHT has been made, should commence
treatment with oral levothyroxine by:
a) CHT positive on initial screening sample
Acceptable standard: 17 days of age (≥99% of infants) 
Achievable standard: 14 days of age (≥99% of infants) 
b) CHT positive on a repeat blood spot sample
Acceptable standard: 24 days of age (≥99% of infants) 
Achievable standard: 21 days of age (≥99% of infants) 
 The EWG found Standard 22 (2005) to be inconsistent with the terminology within other
bloodspot screening programmes and recommended changing to ‘acceptable’ and
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achievable’ standards. They determined that the timeliness of treatment initiation
should prevent severe neurological sequelae but also realistically reflect what was
achievable within the current screening programme.
New Standard 19. The starting dose of oral levothyroxine should be 10-15mcg/kg/day, with a
maximum dose of 50mcg/day. The objective of treatment is to normalise TSH within the first
month. The dose of levothyroxine may need to be reduced if TSH is suppressed or if the baby is
showing signs of overtreatment.
Babies with significant endogenous thyroid hormone production may need smaller initial doses.
(See Note 5)
Note 5: Treatment with levothyroxine should lead to normalisation of free T4 and a 50%
reduction in TSH within days.34 However TSH normalisation can take weeks and timing does not
correlate well with the administered levothyroxine dosage or the severity of the underlying
diagnosis. The aim of treatment is therefore to increase free T4 close to the upper reference
range within the first 2 weeks of treatment and to normalise the TSH within the first month.136
Free T4 concentrations may exceed the normal reference range at the time of TSH normalisation
but significant elevation should be avoided. Regular dose adjustments may be required.
 EWG members agreed that a guide to an appropriate staring dose and upper limit as
important to avert the potential overtreatment due to high starting doses described in
the literature.
New Standard 20. Only licensed solutions and tablets of levothyroxine should be used.
Suspensions may be unreliable. Parents should be shown how to administer preparations and
accompanying written information should be provided.
 EWG members considered it important to define the types of formulation to be used as
suspensions are unreliable in dose but still may be offered to parents. New liquid
formulations are now available as alternatives.
New Standard 21. Once treatment has been started, TSH and thyroid hormone concentration
should be checked at approximately 2 weeks, 4 weeks, 8 weeks, 3 months, 6 months, 9 months
and 12 months after treatment is started, and thereafter as indicated. More intensive
biochemical monitoring may be required.
(See Note 5)
 EWG members considered it important to define more frequent follow-up during the first
year after commencing treatment to ensure that over- and under-treatment was
minimised. Note 5 provides a guide to ensure optimal treatment monitoring and
consistency.
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11 Economic Effectiveness of Screening, Initial Treatment and
Follow-Up Regimes for CHT
11.1 Evidence from the literature review
Only two studies addressing the cost-effectiveness of newborn screening for CHT were
retrieved. Carroll and Downs’ paper was rated good quality (M+) whilst the Geelhoed’s was
rated low quality (L). Neither study was undertaken in the UK.
Carroll and Downs (2006)137 carried out a cost-effectiveness analysis of screening for various
inborn disorders in the USA. Through a discounted costs model, estimating quality-adjusted life-
years and incremental cost-effectiveness ratio computations, they obtained the following
results: For screening for CHT to be cost saving, it would need to have at least 67% sensitivity.
Moreover, screening for CH would become costly if the prevalence would decrease to values
between 3 and 10 times lower than baseline values. In addition, screening would not be cost
saving if the rate of mild developmental delay without treatment was less than one tenth of
baseline values or if the risk of severe delay was decreased by approximately one half. Finally,
screening for CH would not be cost saving if it was less than 67% effective in preventing severe
delay.
Geelhoed and colleagues (2005)138 undertook a cost-benefit analysis for neonatal screening for
PKU and CHT in Australia. They found the annual net saving for screening for CHT was $AUS
1,941,072, while the programme costs were $AUS 581,124 in 2001. Cost savings were primarily
attributable to the avoided costs of caring for an intellectually disabled individual.
Summary
The conclusions from both studies were that newborn screening for CHT as currently practised
was cost-effective and avoids the costs of providing long-term care to affected individuals in
whom the diagnosis is delayed.
11.2 Further Research
Research into the economic effectiveness of newborn screening for CHT in the UK setting is
lacking. Ideally, future studies of the economic effectiveness of CHT screening should consider
longer-term outcomes and quality of life.
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12 Communication with parents
12.1 Introduction
Communication with clinicians and parents was addressed explicitly in the New Standards 10-12,
however members of the EWG also considered the leaflets currently produced by the UKNSPC
and intended for distribution to parents of children with a presumed positive screening result
and after confirmation of the diagnosis.
12.2 Existing leaflets
Two leaflets are currently produced by the UKNSPC:
 ‘When Congenital Hypothyroidism is Suspected’ – for parents of children with a positive
screening result who require further testing
 ‘Congenital hypothyroidism and your child’ – providing parents with information about
the condition and aimed particularly at parents of affected children.
12.3 Revision of parent leaflets
A subgroup of EWG members, including parents, representatives of the UKNSPC and clinicians,
was convened. The subgroup reviewed, revised and updated the parent leaflets. These will be
available as pdf downloads on the UKNSPC website accessible to parents, laboratory staff and
paediatricians.
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Appendix 1: Expert Working Group Terms of Reference and
Membership
UK Newborn Screening Programme Centre (UKNSPC) and British
Society for Paediatric Endocrinology and Diabetes (BSPED)
Joint Standing Committee on Congenital Hypothyroidism (CHT)
Expert Working Group to review Initial Clinical Referral Standards for CHT
2010 – 2011
1. Terms of reference
1.1 To review existing (2005) UKNSPC standards and guidelines to support confirmatory
diagnosis and initial management for babies in whom CHT is suspected
1.2 This will include review of:
 Screening result TSH cut-offs used to determine which infants are referred, not referred
or for whom a repeat test might be indicated (borderline).
 Timeliness of referral by laboratory to designated clinician
 Timeliness of first visit to designated clinician when CHT is suspected on first sample
 Timeliness of repeat test for an initial borderline result
 Timeliness of referral to designated clinician when CHT suspected result is preceded by
borderline result
 Diagnostic schedule for confirmatory diagnosis of CHT
 Initial treatment including starting dose, formulation and instructions to parents
 Frequency of follow up and repeat blood tests
1.3 To agree consultation and approval process for new standards and guidelines
1.4 To agree timetable for this review
1.5 To support the review process with evidence review and expert consensus where published
evidence is lacking
2. Dependencies
2.1 The group will take account of but not revisit the policy on repeat testing of preterm infants
as agreed with BAPM.
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3. Expected outputs
2.1 Primary output of the group will be:
Revised Standards and guidelines for Initial Clinical Referral – including evidence
tables where appropriate.
2.2 The outputs of this review will:
 feed into the CHT laboratory handbook sub group
 need to take account for any recommendations of the BSPED review of managed clinical
networks.
 inform parent information and HCP educational material
4. Reporting arrangements
This sub group will report to the Joint Standing Committee for endorsement and
recommendation.
Recommendations will be ratified by the Blood Spot Advisory Group (BSAG) and submitted to
the Fetal Maternal and Child Health sub Group (FMCH) of the National Screening Committee
(NSC) for approval of any changes to current policy.
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Appendix 2: Expert Working Group Members and Meetings
12.4 Expert Working Group Members
Dr Tim Cheetham Chairman, Consultant Paediatric Endocrinologist and
representative of the British Society for Endocrinology and
Diabetes (BSPED)
Dr Rachel Knowles Clinical Research Fellow, MRC Centre for Epidemiology of Child
Health
Ms Cathy Coppinger Programme Manager, UK Newborn Screening Programme
Centre (UKNSPC)
Ms Radhika Rajani/ Ms
Brielle Woods
Administrators, UKNSPC
Professor John Gregory Consultant Paediatric Endocrinologist and representative of the
British Society for Endocrinology and Diabetes (BSPED)
Dr Jeremy Kirk Consultant Paediatric Endocrinologist and representative of the
British Society for Endocrinology and Diabetes (BSPED)
Dr Catherine Peters Consultant Paediatric Endocrinologist
Ms Jacqui Adkins Parent
Ms Lynn Booth Parent
Melanie Downing Lead Scientist Regional Newborn Screening Laboratory, Sheffield
Childrens NHS Foundation Trust. UK Newborn Screening
Laboratory Network (UKNSLN) representative
Kate Hall Clinical Scientist, West Midland Newborn Screening Laboratory
UK Newborn Screening Laboratory Network (UKNSLN)
representative
Dr Carol Evans Consultant Clinical Scientist
Ms Shirley Langham Clinical Nurse Specialist
Dr Laurence Abernethy Consultant Radiologist
Mr Jez Jones Thyroid Research Assistant
12.5 Experts attending occasional meetings
Ms Freyja Olafsdottir PhD Student
Dr Tony Sirimanna Consultant Paediatric Audiologist
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12.6 Expert Working Group meeting dates
14th October 2010
1st March 2011
7th July 2011
16th September 2011
12.7 Subgroup membership
Subgroup Topic Lead Membership
Diagnostic Test Carol Evans Laurence Abernethy
John Gregory
Jez Jones
Treatment and
Communication
Tim Cheetham
Jez Jones
Catherine Peters
Cathy Coppinger
Referral Pathway and
Clinical Responsibility
Jeremy Kirk Kate Hall
Screening Test Performance Rachel Knowles
Catherine Peters
John Gregory
Kate Hall
Shirley Langham
Melanie Downing
Communication from the
Parent Perspective
Jacqi Adkins
Lynn Booth
Cathy Coppinger
Radhika Rajani
Rachel Knowles
Shirley Langham
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Appendix 3: Dose and timing of therapy across different studies
Table 1: Starting dose and timing of initiation of therapy
Dose Age Reference
2 µg/kg/day 17 days Gunn et al (1996)38
3.2-12.3 µg/kg/day - Rovet (2004)139
2.5/3.75/5 µg/kg/day - Vogiatzi & Kirkland (1997)135
4.5-4.6 µg/kg/day 18-34.88 days Toublanc et al (1998)43
5.1 µg/kg/day 24 days Toublanc et al (1997)140
5.1 µg/kg/7.9 µg/kg/9.1
µg/kg
18.3 days/12 days Rovet & Ehrlich (1995)127
5.6 ± 1.6 µg/kg/d 22.8 ± 6.8 days Leger at al (2001)61
6.4 ± .2 µg/kg/d 26 ± .9 days Salerno et al (2008)49
6.6 ±.9 µg/kg/d 26 ± 4 days Salerno et al (2004)48
6.6 µg/kg/d (range 5.3-9.3
µg/kg/d).
14.5 days (range 2-22 days) Campos et al (1995)36
6.7-8 µg/kg 13.5-17 days Rovet & Alvarez (1996)63
6.8 ± 1.8 µg/kg 28.2 ± 10.8 days Salerno et al (1999)46
6.8 µg/kg/day 24 ± 12 days Moreno et al (1989)120
6.8 µg/kg/d Mean 20 days Kempers et al (2007)72
7 ± 1.8 µg/kg 25 ± 5 days Salerno et al (2001)47
7.6 ± 1.4 µg/kg/day 19.5 ± 14.8 days Mayayo et al (1988)141
7.7 µg/kg (normal hearing),
7.1 µg/kg(hearing
impaired)
13.5 days (normal hearing),
22.3 days (hearing impaired)
Rovet et al (1996)107
7-10 µg/kg/day 35 ± 9.8 days Weber et al (1996)121
7-10.6 µg/kg/day 10.8-18.1 days Bongers-Schokking et al (2005)112
31/120 used 7.6µg/kg/d,
28/120 used 15 µg/kg/d,
53/120 used 11.4 µg/kg/d.
- Jones & Donaldson (2009)130
8 µg/kg/d 17 days Law et al (1998)13
8.1mg/kg/7.8mg/kg 16.7days/16.9days Rovet et al (1987)142
8.4 ± 2 µg/kg/d 33 ± 14 days Battisti et al (1996)58
8.4 ± 3.3 µg/kg/d 24.4 ± 29.9 days Oerbeck et al (2005)41
8.4 ± 3.4µg/kg 18.9 ± 8.6days Heyerdahl et al (1991)60
8.5 µg/kg/day 18.9 ± 8.6 days Heyerdahl et al (1996)71
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Dose Age Reference
8.5 µg/kg/day 24.4 ± 29.2 days Oerbeck et al (2003)42
8.5 ±3.3 µg/kg/d 18.9 ± 8.6 days Heyerdahl (1996)53
8.8 ± 2 µg/kg 12.2 ± 4 days Rovet et al (1989)143
8.8 µg/kg/day 16 days Alvarez et al (2004)30
8-9 µg/kg/day 12-14 days Bakker et al (2002)34
8-10 µg/kg 17 days (range 0-114 days) Tillotson et al (1994)40
8-10 µg/kg/d 15 ± 7 days Ilicki & Larson (1988)22
8-10 µg/kg/d 28 days (range 15-45 days) Bargagna et al (2000)132
8-10 µg/kg/d 30 ± 10 days Bargagna et al (1999)122
8-10.6 µg/kg/d 13-17 days Connelly et al (2001)35
8-10µg/kg/d 16.6 ± 16.2 days Rovet et al (1992)62
9 ± 1.7 mcg/kg/d 17.9 ± 21.9 days Song et al (2001)68
9.03 µg/kg/d Median 25 days Gibert Agullo et al (2010)144
9.1mg/kg 31 days Nakamizo et al (2007)9
9.2 µg/kg/d (range 4-12) 13 days (range 8-30 days) Bongers-Schokking et al (2000)111
9.3 ± 5 µg/kg/d 16.4 ± 22 days Rovet (1999)64 69
9.3 ±5mg/kg 16.25 days Rovet & Hepworth(2002)145
9.8 µg/kg 26.6 days Delvecchio et al (2007)51
10 µg/100cal 29 days NECHC (1984)134
10 µg/kg/day 9 days Mirabella et al (2005)146
10.5 ±0.8µg/kg/d /
7.1 ±1.8µg/kg/d
10.8 days/ 17 days Bongers-Schokking (2001)131
10µg/kg/day 14 days Brown et al (2002)114
10-14 µg/kg/d 4 weeks Germak & Foley (1990)55
10-15 µg/kg/d 8.21 ± 7 days Alvarez (2010)57
10-15 µg/kg/d 9 days (range 5-18 days) Dimitropoulos (2009)32
112.2-12.2 µg/kg/d 13-14 days Simoneau-Roy et al (2004)113
12 µg/kg (7.2-17) 7 days (range 4-15 days) Arenz et al (2008)108
12. µg/kg/d (severe),
11.1µg/kg/d (moderate)
11 days (moderate),
14 days (severe)
Dubuis et al (1996)31
12.5-72 µg/d 7-14 days(n=50), 3-6 weeks(n=10) Winkler et al (1993)67
50 µg/d 18 days (range 10-36 days) Fisher & Foley (1989)52
Final Report (January 2013) 85 | Page
Dose Age Reference
Athyreosis: 15 µg/kg/d,
Ectopia: 12 µg/kg/d,
Dyshormonogenesis: 10
µg/kg/d
2-3 days (positive screen)
or 14 days (borderline)
Mathai et al (2008)29
Group 1: 25 µg/kg,
Group 2: 30-40 µg/kg,
Group 3: 50µg/kg
12 days Jones et al (2009)130
Group 1: 6.3 µg/kg/d,
Group 2: 9.1 µg/kg/d,
Group 3: 13.4 µg/kg/d
21-25 days Salerno et al (2002)45
Group 1; 37.5 µg/d.
Group 2: 62.5 µg/d for 3
days, followed by 37.5
µg/d.
Group 3: 50 µg/d
10.9 days Selva et al (2002)110
- 28-29 days Van der Sluijs et al (2008)125
- 27± 7.6 days Murphy et al (1986)70
- 23-52 days Kooistra et al (2004)128
- 23.9 ± 10.8 days Adachi et al (2003)119
- 28.2 days Bargagna et al (2006)126
- 16.7 days (range 8-130 days) Rovet & Hepworth (2001)147
- Median 23 days (4-41 days) Fuggle et al (1991)148
- 9 days (1988), 9 days (1992) Hopfner et al (2005)11
- 24 days (low confirmatory T4) 37
days (intermediate T4)
Kooistra et al (1996)117
- 15-91 days Illig et al (1987)123
- 12-46 days Kooistra et al (1994)116
- 12-16 days Rovet et al (2000)65
